EP0862560A1 - Substituted 2-anilinopyrimidines useful as protein kinase inhibitors - Google Patents
Substituted 2-anilinopyrimidines useful as protein kinase inhibitorsInfo
- Publication number
- EP0862560A1 EP0862560A1 EP96939171A EP96939171A EP0862560A1 EP 0862560 A1 EP0862560 A1 EP 0862560A1 EP 96939171 A EP96939171 A EP 96939171A EP 96939171 A EP96939171 A EP 96939171A EP 0862560 A1 EP0862560 A1 EP 0862560A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- optionally substituted
- give
- pyrimidineamine
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- This invention relates to substituted 2-anilinopyrimidines, to processes for their preparation, to pharmaceutical compositions containing them, and to their use in medicine.
- Protein kinases participate in the signalling events which control the activation, growth and differentiation of cells in response to extracellular mediators and to changes in the environment. In general, these kinases fall into two groups; those which preferentially phosphorylate serine and/or threonine residues and those which preferentially phosphorylate tyrosine residues [Hanks, S K, Hunter T, FASEB. J. 9, 576-596 (1995)].
- the serine/threonine kinases include for example, protein kinase C isoforms [Newton A C, J. Biol. Chem.
- tyrosine kinases include membrane-spanning growth factor receptors such as the epidermal growth factor receptor [Iwashita S and Kobayashi M. Cellular Signalling 4, 123- 132 (1992)], and cytosolic non-receptor kinases such as p56 lck p59 f yn ZAP-70 and csk kinases [Chan C et al Ann. Rev. Immunol. 12 , 555-592 (1994)].
- membrane-spanning growth factor receptors such as the epidermal growth factor receptor [Iwashita S and Kobayashi M. Cellular Signalling 4, 123- 132 (1992)]
- cytosolic non-receptor kinases such as p56 lck p59 f yn ZAP-70 and csk kinases [Chan C et al Ann. Rev. Immunol. 12 , 555-592 (1994)].
- R 1 is a hydrogen or halogen atom or an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group or a group selected from hydroxyl (-OH), substituted hydroxyl, thiol (-SH), substituted thiol, am o (-NH2), or substituted ammo,
- R 2 and R 3 which may be the same or different, is each an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group,
- R 4 is a hydrogen atom or a straight or branched chain alkyl group
- R 5 is a hydrogen atom or an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group,
- R 6 is a hydrogen or halogen atom or an ammo (-NH2), substituted ammo, nitro, carboxyl (-CO2H) or esterified carboxyl group or a group -X 1 -R 6a where X 1 is a direct bond or a linker atom or group and R 6a is an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group,
- X is a direct bond or a linker atom or group
- R 7 is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloa phatic, aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof
- Halogen atoms represented by the group R 1 and/or R 6 in compounds of formula (1 ) include for example fluorine, chlorine, bromine or iodine atoms
- R 1 , R 2 , R 3 , R 5 and/or R 6a is an optionally substituted straight or branched chain alkyl
- alkenyl or alkynyl group each of said groups may independently be an optionally substituted straight or branched chain C- ⁇ -6 alkyl, e.g. C 1 -3 alkyl, C2-6 alkenyl, e.g. C 2-4 alkenyl, or C -6 alkynyl, e g C2- 4 alkynyl group.
- Such groups include optionally substituted -CH 3 , -CH 2 CH 3 , -(CH 2 ) 2 CH 3 , -CH(CH 3 ) 2 , -(CH 2 ) 3 CH 3 , -CH(CH 3 )CH 2 CH 3 , -CH 2 CH(CH 3 ) 2 , -C(CH 3 ) 3l -(CH 2 ) 4 CH 3 , -(CH 2 ) 5 CH 3 , -CHCH 2 , -CHCHCH 3 , -CH 2 CHCH 2 , -CHCHCH2CH3, -CH2CHCHCH3, -(CH 2 )2CHCH 2 , -CCH, -CCCH3, -CH 2 CCH, -CCCH 2 CH 3 , -CH 2 CCCH 3 , or -(CH 2 ) 2 CCH groups
- the optional substituents which may be present on these groups include one, two, three or more substituents selected from halogen atoms, e
- Substituted hydroxyl groups represented by the group R 1 in compounds of formula (1 ) include -OR 8 groups where R 8 is an optionally substituted straight or branched C 1 -6 alkyl, e.g. methyl or ethyl, C 2 - 6 alkenyl, e g allyl, or C2- 6 alkynyl, e.g. ethynyl group.
- the optional substituents which may be present on these groups include a phenyl group and/or one, two, three or more of the atoms or groups described above in relation to substituents present on alkyl groups represented by R 1
- Substituted thiol groups represented by the group R 1 include -SR 8 groups, wherein R 8 is as just defined.
- R 1 and/or R 6 is a substituted am o group it may be for example a -NHR 9 or -NR 9 R 10 group where R 9 and R 10 , which may be the same or different, is each a group -R 8 or -COR 8 where R 8 is as just defined
- Esterified carboxyl groups represented by the group R 6 include groups of formula -C0 2 Alk 1 wherein -C ⁇ 2Alk 1 is as defined hereinafter in connection with esterified carboxyl groups represented by the group R 13 .
- Linker atoms represented by X or X 1 in compounds of formula (1 ) include -0- or -S- atoms.
- X or X 1 is a linker group it may be for example a -C(O)-, -C(S)- ( -S(O)-, -S(0) 2 -, -N(RH)- [where RU is a hydrogen atom or a C- 1 -6 alkyi, e.g.
- R 7 in compounds of formula (1 ) is an optionally substituted aliphatic or cycloaliphatic group it may be an optionally substituted C- ⁇ - 10 aliphatic or C3- 1 0 cycloaliphatic group.
- Particular examples include optionally substituted straight or branched chain C-i-e alkyl, C2-6 alkenyl, or C2-6 alkynyl groups or optionally substituted C 3- ⁇ ocycloalkyl, C 3- ⁇ ocycloalkenyl or C 3- iocycloalkynyl groups.
- Heteroaliphatic or heterocycloaliphatic groups represented by R 7 include the aliphatic or cycloaliphatic groups just described but with each group additionally containing one, two, three or four heteroatoms or heteroatom- containing groups. Particular heteroatoms or groups include atoms or groups -X 2 - where X 2 is as defined above for X when X is a linker atom or group.
- Aromatic groups represented by R 7 in compounds of formula (1 ) include for example optionally substituted monocyclic or bicyclic fused ring C6- 1 2 aromatic groups, such as optionally substituted phenyl, 1 - or 2-naphthyl, 1 - or 2-tetrahydronaphthyl, indanyl or indenyl groups.
- Heteroaromatic groups represented by R 7 include optionally substituted C- ⁇ -9 heteroaromatic groups containing for example one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms.
- the heteroaromatic groups may be for example monocyclic or bicyclic fused ring heteroaromatic groups.
- Monocyclic heteroaromatic groups include for example five- or six-membered heteroaromatic groups containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms.
- Bicyclic heteroaromatic groups include for example nine- to thirteen-membered fused-ring heteroaromatic groups containing one, two or more heteroatoms selected from oxygen, sulphur or nitrogen atoms.
- R 7 is a heteroaliphatic, heterocycloaliphatic or heteroaromatic group it is attached to the remainder of the molecule of formula (1 ) through any available heteroatom or group or, preferably, carbon atom.
- R 7 aliphatic groups include those alkyl, alkenyl or alkynyl groups specifically described above in relation to the groups R 1 , R 2 , R 3 , R 5 and R 6 . Each of these groups may be optionally substituted, and/or optionally interrupted by one or two heteroatoms or heteratom- containing groups represented by -X 2 - [where X 2 is as previously defined], to yield particular examples of R 7 optionally substituted aliphatic or heteroaliphatic groups.
- R 7 cycloaliphatic and heterocycloaliphatic groups include optionally substitued cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycioheptyl, 2-cyclobuten-l -yl, 2-cyclopenten-1 -yl, 3- cyclopenten-1 -yl, 2,4-cyclopentadien-1 -yl, 3,5,-cyclohexadien-1 -yl, pyrroline, e.g. 2- or 3-pyrrolinyl, pyrrolidinyl, dioxolanyl, e.g.
- heteroaromatic groups represented by R 7 include optionally substituted pyrrolyl, furyl, thienyl, imidazolyl, N-methylimidazolyl, N-ethyl- imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl,
- R 1 2 substituents which may be present on any of the above R 7 groups in compounds of formula (1 ) include one, two, three or more substituents, each represented by the group R 1 2 .
- the substituent R 1 2 may be selected from an atom or group R 13 or -Alk(R 3 ) m , where R 13 is a halogen atom, or an amino (-NH 2 ), -NHR 14 [where R 14 is an -Alk(R 13 ) m , heterocycloalkyl, -Alk-heterocycloalkyl, aryl or heteroaryl group], -N(R 1 ) 2 [where each R 14 group is the same or different], nitro, cyano, hydroxyl (-OH), -OR 14 , formyl, carboxyl (-C0 2 H), esterified carboxyl, thiol (-SH), -SR 1 4 , -COR 1 4 , -CSR 1 4 , -S
- R 13 may be present on any suitable carbon atom in -Alk Where more than one R 13 substituent is present these may be the same or different and may be present on the same or different atom in -Alk or in R 7 as appropriate
- R 7 may represent a -CH(R 13 ) 2 group, such as a -CH(OH)Ar group where Ar is an aryl or heteroaryl group as defined below
- m is zero and no substituent R 13 is present the alkylene, alkenylene or alkynylene chain represented by Alk becomes an alkyl, alkenyl or alkynyl group.
- R 1 3 is a halogen atom it may be for example a fluorine, chlorine, bromine, or iodine atom
- Esterified carboxyl groups represented by the group R 13 include groups of formula -C0 2 Alk 1 wherein Alk 1 is a straight or branched, optionally substituted C I - ⁇ alkyl group such as a methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl or t-butyl group; a C6- ⁇ 2 arylC ⁇ -8alkyl group such as an optionally substituted benzyl, phenylethyl, phenylpropyl, 1 -naphthyl- methyl or 2-naphthylmethyl group; a C6- ⁇ 2 aryl group such as an optionally substituted phenyl, 1 -naphthyl or 2-naphthyl group; a C6- ⁇ 2 aryloxyC-
- Alk When Alk is present in or as a substituent R 2 it may be for example a methylene, ethylene, n-propylene, i-propylene, n-butylene, i-butylene, s-butylene, t-butylene, ethenylene, 2-propenylene, 2-butenylene , 3-butenylene, ethynylene, 2-propynylene, 2-butynylene or 3-butynylene chain, optionally interrupted by one, two, or three -O- or -S-, atoms or -S(O)-, -S(0) 2 - or -N(R 1 )- groups
- Optionally substituted cycloalkyl groups represented by the group R 1 3 include optionally substituted C 5-7 cycloalkyl groups such as optionally substituted cyclopentyl or cyclohexyl groups.
- Heterocycloalkyl groups represented by the group R 12 or R 4 include optionally substituted heteroC 3-6 cycloalkyl groups containing one or two oxygen, sulphur or nitrogen atoms. Particular examples of such groups include optionally substituted azetid yl pyrrolidinyl, pipe ⁇ dinyl, piperazmyl, homopiperazinyl, morpholinyl or thiomorphol yl groups.
- the heterocyclo- alkyl group may be attached to the remainder of the molecule through any of its ring carbon atoms, or where present, ring nitrogen atom.
- Alk may be as defined above and the heterocycloalkyl portion may be as just defined, attached to Alk through any of its ring carbon atoms, or where present, ring nitrogen atom.
- Optional subsituents which may be present on R 12 , R 13 or R 4 cycloalkyl or heterocycloalkyl groups include one or two C 1 -6 alkyl, e.g. methyl or ethyl, hydroxyl (-OH) hydroxyC-
- the subst ⁇ tuent(s) may be present on any available ring carbon or nitrogen atom as appropriate.
- Aryl and heteroaryl groups represented by the groups R 1 3 or R 4 include for example optionally substituted monocyclic or bicyclic C 6- -
- Particularly useful atoms or groups represented by R 12 include fluorine, chlorine, bromine or iodine atoms, or Chalky!, C 1 -6 alkylamino, d - 6 hydroxyalkyl, C ⁇ -6 alkylthiol, d- 6 alkoxy, hydroxyd-ealkoxy, aminod- 6 alkoxy, d-6alkylarr.inod-6a.koxy, C ⁇ -6 dialkylaminoC ⁇ -6 alkoxy, optionally substituted C 5 - cyclo-alkoxy, optionally substituted C -7 cycloalkyl, optionally substituted C 5 -7cycloalkylamino, haloC 1 -6 alkyl, halod-ealkoxy, C ⁇ -6 alkylamino, amino (-NH 2 ), aminoC ⁇ .
- two R 12 substituents may be linked together to form a cyclic group such as a cyclic ether, e.g. a d- ⁇ alkylenedioxy group such as a methylenedioxy or ethylenedioxy group
- R 12 substituents include for example fluorine, chlorine, bromine or iodine atoms, or a methylamino, ethylamino, hydroxymethyl, hydroxyethyl, methylthiol, ethylthiol, methoxy, ethoxy, ⁇ -propoxy, 2- hydroxyethoxy, 3-hydroxypropoxy, 4-hydroxybutoxy, 2-am ⁇ noethoxy, 3- ammopropoxy, 2-(methylam ⁇ no)ethoxy, 2-(d ⁇ methylam ⁇ no)ethoxy, 3- (d ⁇ methylam ⁇ no)propoxy, cyclopentyloxy, cyclohexyl, cyclohexylammo, 2- hydroxycyclohexylammo, trifluoromethyl, tnfiuoromethoxy, methylamino, ethylamino, ammo (-NH) 2 , aminomethyl, aminoethyl, dimethylamino, dieth
- R 12 substituents are present, these need not necessarily be the same atoms and/or groups.
- the presence of certain substituents in the compounds of formula (1 ) may enable salts of the compounds to be formed.
- Suitable salts include pharmaceutically acceptable salts, for example acid addition salts derived from inorganic or organic acids, and salts derived from inorganic and organic bases.
- Acid addition salts include hydrochlorides, hydrobromides, hydroiodides, alkylsulphonates, e.g. methanesulphonates, ethanesulpho ⁇ ates, or isethionates, arylsulphonates, e.g. p-toluenesulphonates, besylates or napsylates, phosphates, sulphates, hydrogen sulphates, acetates, tnfluoroacetates, propionates, citrates, maleates, fumarates, malonates, succmates, lactates, oxalates, tartrates and benzoates.
- Salts derived from inorganic or organic bases include alkali metal salts such as sodium or potassium salts, alkaline earth metal salts such as magnesium or calcium salts, and organic am e salts such as morpholine, piperidine, dimethylamine or diethylamine salts.
- Particularly useful salts of compounds according to the invention include pharmaceutically acceptable salts, especially acid addition pharmaceutically acceptable salts.
- the compounds of formula (1) may exist as geometrical isomers and/or may have one or more chiral centres so that enantiomers or diasteromers may exist. It is to be understood that the invention extends to all such isomers of the compounds of formula (1 ), and to mixtures thereof, including racemates.
- the groups R , R 2 , R 3 , R 4 , R5_ R 7 and X are as defined for formula (1 ), as is the group R 6 except it is not an am o, substituted am o, nitro, carboxyl or esterified carboxyl group.
- R 2 and R 3 is each an optionally substituted methyl or ethyl group.
- groups of these types include methyl, ethyl, halomethyl, e.g. -CH 2 F, -CH 2 CI, -CHF 2 , -CHCI 2 , -CF 3 , -CCI 3 , or haloethyl groups.
- R 2 and R 3 is each preferably a methyl group.
- R 1 may in particular be an optionally substituted methoxy group.
- R 1 groups include -OCH 2 F, -OCH 2 CI, -OCHF2, -OCHCI2, -OCF 3l -OCCI3 or, especially, methoxy groups.
- R 4 is preferably a hydrogen atom.
- the groups R 5 and R 6 in compounds of formula (1 ) are each preferably a hydrogen atom.
- X in compounds of formula (1 ) is a direct bond, an oxygen or sulphur atom or a -N(R 1 1 )- group.
- Especially useful compounds of this type are those whereinX is a direct bond, a sulphur atom or a -N(R 1 1 )-, particularly a -NH-, group.
- R 7 in compounds of formula (1) is preferably an optionally substituted aromatic or heteroaromatic group.
- a further class of compounds according to the invention has the formula 1 (a):
- R 5 and R 6 are as defined for formula (1 ), X is a direct bond, an oxygen or sulphur atom, or a group -N(R 1 1 )- and R 7 is an optionally substituted aromatic or heteroaromatic group, and the salts, solvates, hydrates and N-oxides thereof.
- R 5 is preferably a hydrogen atom.
- R 6 is preferably a group -X R 6a where X 1 is as defined for formula (1 ) and R 6 a is an optionally substituted straight or branched chain alkyl group, or R 6 is especially a hydrogen atom.
- X in compounds of formula (1 a) is preferably a direct bond, a sulphur atom, or a -N(R 1 1 )- group, particularly a -NH-group.
- R 7 group in compounds of formulae (1 ) or 1 (a) in general may be as defined previously for compounds of formula (1 ).
- R 7 is an optionally substituted phenyl, 1 - or 2-naphthyl or heteroaromatic group containing one or two oxygen, sulphur and/or nitrogen atoms.
- R 7 may be an optionally substituted phenyl, 1 - or 2-naphthyl, pyrrolyl, furyl, thienyl, indolyl, pyrazolyl, thiazolyl, [2,3-d ⁇ hydro]benzofuryl, benzothiazolyl, 2-pyr ⁇ dyl, 3- pyridyl or 4-py ⁇ dyl group.
- Particularly useful groups include optionally substituted phenyl, 2-py ⁇ dyl, 3-pyr ⁇ dyl or 4-py ⁇ dyl groups.
- the aromatic or heteroaromatic group may in particular be attached to the remainder of the compound of formula (1 ) through any available ring carbon atom.
- the optional substituents which may be present on aromatic or heteroaromatic R 7 groups in compounds of formulae (1 ) or (1 a) include one, two, or three R 12 substituents as generally and particularly described above and hereinafter in the Examples.
- Particularly useful R 1 2 substituents include -NHR 14 , -AlkNH 2 , -AlkNHR 14 , -OR 14 , -AlkC0 2 H or -AlkC0 2 Alk 1 groups where R 4 , Alk and Alk 1 are as generally and particularly defined above.
- Useful members of these substituents include those wherein R 14 is an -Alk, -AlkNH2 or -Alk-heterocycloalkyl group. In t hese, and the other preferred substituents just mentioned, Alk and Alk 1 when present is each preferably a d -6alkyl group.
- Particularly useful compounds according to the invention include: N,N'-Bis(3,4,5-Tr ⁇ methoxyphenyl)-2,4-pyr ⁇ m ⁇ d ⁇ ned ⁇ am ⁇ ne; 4-(2-(2-D ⁇ methylam ⁇ noethylam ⁇ no)pyr ⁇ d ⁇ n-5-yl)-N-(3,4,5-tr ⁇ methoxyphenyl)- 2-py ⁇ m ⁇ d ⁇ neam ⁇ ne,
- Compounds according to the invention are potent and selective inhibitors of protein kinases as demonstrated by differential inhibition of enzymes such as EGFr kinase, p56 lck kinase, ZAP-70 kinase, Csk kinase and p59 f y n kinase
- enzymes such as EGFr kinase, p56 lck kinase, ZAP-70 kinase, Csk kinase and p59 f y n kinase
- the compounds according to the invention are thus of particular use in the prophylaxis and treatment of diseases in which inappropriate protein tyrosine kinase action plays a role, for example in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus, in transplant rejection, in graft v host disease, in hyperproliferative disorders such as tumours, psoriasis, in pannus formation in rheumatoid arthritis, restenosis following angioplasty and atherosclerosis, and in diseases in which cells receive pro-inflammatory signals such as asthma, inflammatory bowel disease and pancreatitis
- the compounds according to the invention may be administered as pharmaceutical compositions, and according to a further aspect of the invention we provide a pharmaceutical composition which comprises a compound of formula (1) together with one or more pharmaceutically acceptable carriers, excipients or diluents
- compositions according to the invention may take a form suitable for oral, buccal, parenteral, nasal, topical or rectal administration, or a form suitable for administration by inhalation or insufflation
- the pharmaceutical compositions may take the form of, for example, tablets, lozenges or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e g pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e g lactose, microcrystalline cellulose or calcium hydrogen phosphate), lubricants (e g magnesium stearate, talc or silica), disintegrants (e g potato starch or sodium glycollate), or wetting agents (e g sodium lauryl sulphate)
- binding agents e g pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
- fillers e g lactose, microcrystalline cellulose or calcium hydrogen phosphate
- lubricants e g magnesium stearate, talc or silica
- disintegrants e g potato starch or sodium glycollate
- wetting agents e g sodium
- Preparations for oral administration may be suitably formulated to give controlled release of the active compound
- compositions may take the form of tablets or lozenges formulated in conventional manner
- the compounds for formula (1 ) may be formulated for parenteral administration by injection e.g. by bolus injection or infusion.
- Formulations for injection may be presented in unit dosage form, e.g. in glass ampoule or multi dose containers, e.g. glass vials.
- the compositions for injection may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising, preserving and/or dispersing agents.
- the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
- the compounds of formula (1 ) may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation or by intramuscular injection.
- the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation for pressurised packs or a nebuliser, with the use of suitable propellant, e.g. dichlorodifluoromethane, trichloro- fluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.
- suitable propellant e.g. dichlorodifluoromethane, trichloro- fluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.
- compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
- the pack or dispensing device may be accompanied by instructions for administration.
- the quantity of a compound of the invention required for the prophylaxis or treatment of a particular condition will vary depending on the compound chosen, and the condition of the patient to be treated. In general, however, daily dosages may range from around 100ng/kg to 100mg/kg e.g. around 0.01 mg/kg to 40mg/kg body weight for oral or buccal administration, from around 10ng/kg to 50mg/kg body weight for parenteral administration and around 0.05mg to around 1000mg e.g. around 0.5mg to around 1000mg for nasal administration or administration by inhalation or insufflation.
- the compounds of the mvention may be prepared by a number of processes as generally described below and more specifically in the Examples hereinafter.
- R 1 -R 7 and X when used in the formulae depicted are to be understood to represent those groups described above in relation to formula (1 ) unless otherwise indicated.
- reactive functional groups for example hydroxy, amino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions.
- Conventional protecting groups may be used in accordance with standard practice [see, for example, Green, T. W. in "Protective Groups in Organic Synthesis", John Wiley and Sons, 1981 ].
- deprotection may be the final step in the synthesis of a compound of formula (1 ) and the processes according to the invention described hereinafter are to be understood to extend to such removal of protecting groups.
- a compound of formula (1) wherein X is a direct bond may be prepared by reaction of a guanidine of formula (2):
- R 1 5 and R 1 6 which may be the same or different is each a C 1 -6 alkyl group.
- the reaction may be performed in a solvent, for example a protic solvent such as an alcohol, e.g. ethanol, methoxyethanol or propanol, optionally in the presence of a base e.g. an alkali metal base, such as sodium hydroxide or potassium carbonate, at an elevated temperature, e.g. the reflux temperature.
- a protic solvent such as an alcohol, e.g. ethanol, methoxyethanol or propanol
- a base e.g. an alkali metal base, such as sodium hydroxide or potassium carbonate
- Salts of the compounds of formula (2) include acid salts such as inorganic acid salts e.g. hydrochlorides or nitrates.
- the reaction may be performed in a solvent such as ethanol at an elevated temperature, e.g. up to the reflux temperature.
- a solvent such as ethanol
- the reaction may be performed in the presence of a concentrated acid, e.g. hydrochloric or nitric acid.
- the anilines of formula (4) are either known compounds or may be obtained by conventional procedures, for example by hydrogenation of the corresponding nitro derivatives using for example hydrogen in the presence of a metal catalyst in a suitable solvent, for example as more particularly described in the interconversion reactions discussed below or by use of the corresponding nitro derivative and a reducing agent such as a sodium hydrosulphite in a solvent such as ethanol at an elevated temperature such as the reflux temperature.
- the nitrobenzenes for this particular reaction are either known compounds or may be prepared using similar methods to those used for the preparation of the known compounds, for example by treatment of the corresponding benzene with nitric acid in the prsence of an acid such as acetic acid at around ambient to the reflux temperature
- Intermediate enam ones of formula (3) may be prepared by reaction of an acetyl derivative R 7 COCH 2 R 6 with an acetal (R 16 )(R 5 )NCR 5 (OCH 3 ) 2 at an elevated temperature
- the starting materials for this reaction are either known compounds of may be prepared by methods analogous to those used for the preparation of the known compounds.
- a compound of formula (1 ) where X is a linker atom or group may be prepared by reaction of an intermediate of formula (5)
- L is a leaving atom or group
- R X 2 H where X 2 is a linking atom or group as defined above.
- Particular leaving atoms or groups represented by L include for example halogen atoms, e.g. bromine, iodine or chlorine atoms, and sulphonyloxy groups, e.g. alkylsulphonyloxy groups, such as t ⁇ fluoromethylsulphonyl- oxy, and aryisulphonyloxy groups, such as p-toluenesulphonyloxy
- halogen atoms e.g. bromine, iodine or chlorine atoms
- sulphonyloxy groups e.g. alkylsulphonyloxy groups, such as t ⁇ fluoromethylsulphonyl- oxy
- aryisulphonyloxy groups such as p-toluenesulphonyloxy
- the reaction may be performed in the presence of a base, for example an organic base such as an organic amme, e.g triethylamine or an inorganic base, for example a hydride such as sodium hydride, an alkoxide such as potassium t-butoxide, or a carbonate such as caesium or potassium carbonate, where necessary in the presence of a dipolar aprotie solvent such as an ether, e.g. a cyclic ether such as tetrahydrofuran, or an amide, e.g. a substituted amide such as dimethylformamide, at a suitable temperature e g from around room temperature to around 90°C
- a base for example an organic base such as an organic amme, e.g triethylamine or an inorganic base, for example a hydride such as sodium hydride, an alkoxide such as potassium t-butoxide, or a carbonate such as caesium or potassium carbonate, where
- the starting py ⁇ midinones may be prepared by reaction of a guanidine of formula (2) or a salt thereof with a ⁇ -ketoester [for example a compound CH 3 CH 2 C (0)OCH(R 6 )C(0)R 5 (where R5 IS an optionally substituted alkyl, alkenyl or alkynyl group)] or a functional analogue thereof where it is desired to obtain compounds wherein R 5 is a hydrogen atom, in the presence of a base, for example an alkoxide such as sodium methoxide in a solvent, for example a protic solvent, such as an alcohol, e g methanol at an elevated temperature, e g up to around the reflux temperature
- a base for example an alkoxide such as sodium methoxide in a solvent, for example a protic solvent, such as an alcohol, e g methanol at an elevated temperature, e g up to around the reflux temperature
- a compound of formula (1 ) may be prepared by displacement of a leaving atom or group in a pyrimidine of formula (6)
- the reaction may be performed at an elevated temperature, for example the reflux temperature, where necessary in the presence of a solvent, for example a ketone such as acetone, an alcohol such as ethanol or 2- ethoxyethanol or an aromatic hydrocarbon such as toluene, optionally in the presence of a base, for example an organic amme such as triethylamide or pyridine, or an acid, for example an inorganic acid such as hydrochloric acid.
- a solvent for example a ketone such as acetone
- an alcohol such as ethanol or 2- ethoxyethanol
- an aromatic hydrocarbon such as toluene
- a base for example an organic amme such as triethylamide or pyridine
- an acid for example an inorganic acid such as hydrochloric acid.
- the pyrimidines of formula (7) and the nucleophilic reagents R 7 XH are either known compounds or may be prepared using methods analogous to those used for the preparation of the known compounds.
- a compound of formula (1 ) wherein X is a -C(O)- group may be prepared by treating a carboxamide of formula (8):
- the group X 3 in intermediates of formula (8) may be for example a group -CONR 1 5R 16 or -CON(R 15 )(OR 1 6).
- the reaction may be performed in a solvent such as an ether, e.g. a cyclic ether such as a tetrahydrofuran, at a low temperature, e g around -78°C.
- a solvent such as an ether, e.g. a cyclic ether such as a tetrahydrofuran, at a low temperature, e g around -78°C.
- a reactive derivative thereof with a reagent R 15 R 16 NH or R 15 R 1 60NH in the presence of a base e.g. an organic amme such as tnet hylamine in a solvent such as dichloromethane at a low temperature, e.g. around -20° to 0°C.
- a base e.g. an organic amme such as tnet hylamine in a solvent such as dichloromethane at a low temperature, e.g. around -20° to 0°C.
- Intermediate acids of formula (9) may be prepared by heating the corresponding nitrile in the presnce of a base such as sodium hydroxide in a solvent such as ethanol.
- the nitrile starting material may be prepared by heating 2-chloro-4-cyano-pyhmidine with the appropriate aniline in the presence of a base such as triethylamine in a solvent such as ethanol at the reflux temperature.
- Acids of formula (9) may also be used to generate compounds of formula (1 ) wherein X is a -NHC(0)0- group by reaction with an azide, for example diphenylphosphorylazide, and an alcohol R OH in the presence of a base such as triethylamine at an elevated temperature, e.g. the reflux temperature.
- an azide for example diphenylphosphorylazide
- R OH an alcohol
- a base such as triethylamine
- Compounds of formula (1 ) may also be prepared by interconversion of other compounds of formula (1 ) and it is to be understood that the invention extends to such interconversion processes.
- standard substitution approaches employing for example alkyiation, arylation, aeylation, thioacylation, sulphonylation, formylation or coupling reactions may be used to add new substitutents to and/or extend existing substituents in compounds of formula (1 ).
- Altematively existing substituents in compounds of formula (1 ) may be modified by for example oxidation, reduction or cleavage reactions to yield other compounds of formula (1 ).
- the alkyiation or arylation reaction may be carried out in the presence of a base, e.g. an inorganic base such as a carbonate, e g. caesium or potassium carbonate, an alkoxide, e g. potassium t-butoxide, or a hydride, e.g. sodium hydride, in a dipolar aprotie solvent such as an amide, e.g. a substituted amide such as dimethylformamide or an ether, e g. a cyclic ether such as tetrahydrofuran, at around 0°C to around 40°C
- a base e.g. an inorganic base such as a carbonate, e g. caesium or potassium carbonate, an alkoxide, e g. potassium t-butoxide, or a hydride, e.g. sodium hydride
- a dipolar aprotie solvent such as an amide,
- the leaving group L may be alternatively part of the compound of formula (1 ) and the reaction performed with an appropriate nucleophilic reagent in a solvent such as an alcohol, e g ethanol, at an elevated temperature, e.g the reflux temperature.
- a solvent such as an alcohol, e g ethanol
- a compound of formula (1 ) may be acylated or thioacylated
- the reaction may be performed for example with an acyl halide or anhydride in the presence of a base, such as a tertiary amme e g triethylamine in a solvent such as a halogenated hydrocarbon, e.g dichloromethane or carbon tetrachloride, or an alcohol, e.g methanol at for example ambient temperature, or by reaction with a thioester in an inert solvent such as tetrahydrofuran at a low temperature such as around 0°C
- a base such as a tertiary amme e g triethylamine
- a solvent such as a halogenated hydrocarbon, e.g dichloromethane or carbon tetrachloride, or an alcohol, e.g methanol at for example ambient temperature
- a thioester in an inert solvent such
- a compound of formula (1 ) may be formylated, for example by reaction of the compound with a mixed anhydride HCOOCOCH3 or with a mixture of formic acid and acetic anhydride
- Compounds of formula (1 ) may be prepared in another general interconversion reaction by sulphonylation, for example by reaction of the compound with a reagent AlkS(O) 2 L, or ArS(O)2L in the presence of a base, for example an inorganic base such as sodium hydride in a solvent such as an amide, e.g a substituted amide such as dimethylformamide at for example ambient temperature
- a base for example an inorganic base such as sodium hydride in a solvent such as an amide, e.g a substituted amide such as dimethylformamide at for example ambient temperature
- the reaction may in particular be performed with compounds of formula (1 ) possessing a primary or secondary ammo group
- compounds of formula (1 ) may be prepared from other compounds of formula (1 ) by modification of existing functional groups in the latter
- ester groups -C0 2 Alk 1 in compounds of formula (1 ) may be converted to the corresponding acid [-C0 2 H] by acid- or base- catalysed hydrolysis or by catalytic hydrogenation depending on the nature of the group Alk 1
- Acid- or base-catalysed hydrolysis may be achieved for example by treatment with an organic or inorganic acid , e g trifluoroacetic acid in an aqueous solvent or a mineral acid such as hydrochloric acid in a solvent such as dioxan or an alkali metal hydroxide, e.g lithium hydroxide in an aqueous alcohol, e g aqueous methanol
- Catalytic hydrogenation may be carried out using for example hydrogen in the presence of a metal catalyst, for example palladium on a support such as carbon in a solvent such as an ether, e g tetrahydrofuran or an alcohol , e g methanol
- base-catalysed hydrolysis with for example an organic
- -OAlk 2 [where Alk 2 represents an alkyl group such as a methyl group] groups in compounds of formula (1 ) may be cleaved to the corresponding alcohol [-OH] by reaction with boron tribromide in a solvent such as a halogenated hydrocarbon, e g dichloromethane at a low temperature, e g around -78°C
- a solvent such as a halogenated hydrocarbon, e g dichloromethane at a low temperature, e g around -78°C
- Alcohol [-OH] groups may also be obtained by hydrogenation of the corresponding -OCH 2 Ar group using for example hydrogen in the presence of a metal catalyst, for example palladium on a support such as carbon in a solvent such as ethanol in the presence of ammonium formate
- a metal catalyst for example palladium on a support such as carbon in a solvent such as ethanol in the presence of ammonium formate
- -OH groups may be generated from the corresponding ester [-C ⁇ 2Alk] by reduction using for example a complex metal hydride such as lithium aluminium hydride.
- alcohol -OH groups in compounds of formula (1 ) may be converted to a corresponding -OAlk or -OAr group by coupling with a reagent AlkOH or ArOH in a solvent such as tetrahydrofuran in the presence of a phosphine, e.g triphenylphosphine and an activator such as diethyl-, diisopropyl-, or dimethylazodicarboxylate.
- a phosphine e.g triphenylphosphine and an activator such as diethyl-, diisopropyl-, or dimethylazodicarboxylate.
- amines of formula (1) may be alkylated using a reductive alkyiation process employing an aldehyde and a borohydride, for example sodium t ⁇ acetoxyborohyd ⁇ de, in a solvent such as dichloromethane, in the presence of an acid such as acetic acid at around ambient temperature
- a reductive alkyiation process employing an aldehyde and a borohydride, for example sodium t ⁇ acetoxyborohyd ⁇ de, in a solvent such as dichloromethane, in the presence of an acid such as acetic acid at around ambient temperature
- Aminosulphonylammo [-NHSO2NH2] groups in compounds of formula (1 ) may be obtained, in another example, by reaction of a corresponding amme [-NH2] with sulphamide in the presence of an organic base such as pyridine at an elevated temperature, e g the reflux temperature
- amme [-NH2] groups in compounds of formula (1 ) may be obtained by hydrolysis from a corresponding imide by reaction with hydrazine in a solvent such as an alcohol, e g ethanol at ambient temperature.
- a nitro [-NO2] group may be reduced to an amme [- NH 2 ], for example by catalytic hydrogenation as just described, or by chemical reduction using for example a metal, e.g. tin or iron, in the presence of an acid such as hydrochloric acid, optionally in a solvent such as an alcohol, e.g. methanol
- a tetrazole substituent may be obtained from the corresponding nitrile by treatment of the latter with an azide, e.g. sodium azide, in a solvent such as a substituted amine, e.g. dimethylformamide at an elevated temperature.
- N-oxides of compounds of formula (1 ) may be prepared for example by oxidation of the corresponding nitrogen base using an oxidising agent such as hydrogen peroxide in the presence of an acid such as acetic acid, at an elevated temperature, for example around 70°C to 80°C, or altematively by reaction with a peracid such as peracetic acid or 3- chloroperoxybenzoic acid in a solvent, e.g. dichloromethane, at ambient temperature.
- salts of compounds of formula (1 ) may be prepared by conventional means, for example by reaction of a compound of formula (1 ) with an appropriate acid or base in a suitable solvent or mixture of solvents, e.g. an organic solvent such as an ether, e.g. diethylether, or an alcohol, e.g. ethanol.
- a suitable solvent or mixture of solvents e.g. an organic solvent such as an ether, e.g. diethylether, or an alcohol, e.g. ethanol.
- the guanidine starting material was prepared by heating a mixture of
- EXAMPLE 3 4-(4-Pyridv ⁇ -N- ( 3.4.5-trimethoxypheny ⁇ -2-pyrimidineamine from 3,4,5-(tr ⁇ methoxyphenyl)guan ⁇ d ⁇ ne nitrate (1.44g, 5. Ommol), 3- d ⁇ methylam ⁇ no-1 -(4-pyr ⁇ dyl)-2-propene-1 -one (880mg, 5. Ommol) and sodium hydroxide (220mg, 5.5mmoi) to give the title compound (765mg) as a green solid m.p. 205°.
- EXAMPLE 4 4-(2-Furyl)-N-3.4.5-ttrimetho ⁇ y p henyn-2-pyrimidineamine from 3,4,5-(trimethoxyphenyl)guanidine nitrate (1 .66g, 5.75mmol), 3- d ⁇ methylamino-1 -(2-furyl)-2-propen-1 -one) (950mg, 5.75mmol) and sodium hydroxide (253mg, 6.33 mmol) to give the title compound (350mg) as a yellow solid m.p. 139°.
- EXAMPLE 8 4- ⁇ 2-Thiazolv ⁇ -N- ⁇ 3.4.5-trimethoxyphenvn-2-pyrimidineamine from 3,4,5-(tr ⁇ methoxyphenyl)guanid ⁇ ne nitrate (1 .27g, 4.40mmol) , 3- d ⁇ methylam ⁇ no-1 -(2-th ⁇ azolyl)-2-propen-1 -one (802mg, 4 40mmol), and sodium hydroxide (194mg, 4.84mmol) to give the title compound (520mg) as a green solid m.p. 159°.
- EXAMPLE 10 4- ( 2-Naphthvh-N- ( 3.4.5-trimetho ⁇ y p henyl ) -2-pyrimidineamine from 3,4,5-(trimethoxypheny)guanidine nitrate (1.02g, 3.55mmol), 3- dimethylamino-1 -(2-naphthyl)-2-propen-1 -one (800mg, 3.55mmol) and sodium hydroxide (156mg, 3.90mmol) to give the title compound (310mg) as a yellow solid m.p. 156°.
- EXAMPLE 11 4- ( 3-Nitrophenyn-N-(3.4.5-trimethoxyphenvn-2- p yrimidineamine from 3,4,5-(trimethoxyphenyi)guanidine nitrate (3.93g, 13.63mmol), 3- dimethylamino-1-(3-nitrophenyl)-2-propen-1 -one (3.0g, 13.63mmol) and sodium hydroxide (545mg, 13.63mmol) to give the title compound (250mg) as a yellow solid, m.p. 184-185°. MS m/z 383 (M+H)+.
- EXAMPLE 13 4-(3-Bromopheny ⁇ -N-(3.4.5-trimethoxyphenyl)-2-pyrimidineamine from 3,4,5-(trimethoxyphenyl)guanidine nitrate (1.63g, 5.66mmol), 1 -(3- bromophenyl)-3-dimethylamino-2-propen-1-one (1.5g, 5.66mmol) and sodium hydroxide (250mg, 6.23mmol) to give the title compound (785mg) as a yellow solid m.p. 145°. MS m/z 418 (M+H) + .
- EXAMPLE 14 4- ⁇ , Pyrrpl-2-vh-N-f3.4.5-trimethoxypheny ⁇ -2-pyrimidineamine from 3,4,5-(trimethoxyphenyl)guanidine nitrate (1.15g, 4. Ommol), 3- dimethylamino-1 -(pyrrol-2-yl)-2-propen-1 -one (656g, 4. Ommol) and sodium hydroxide (176mg, 4.4mmol) to give the title compound (10mg) as a yellow solid m.p. 150°. MS m/z 327 (M+H) + .
- EXAMPLE 16 4-(Pyrazin-2-y ⁇ -N-f3.4.5-trimethoxyphenyl)-2-pyrimidineamine from 3,4,5-(trimethoxyphenyl)guanidine nitrate (1.15g, 4. Ommol), 3- dimethylamino-1 -(pyrazin-2-yl)-2-propen-1 -one (708mg, 4. Ommol) and sodium hydroxide (176mg) to give the title compound (254mg) as a yellow solid, m.p. 181-182°. MS m/z 340 (M+H) + .
- EXAMPLE 20 4-rBenzothiazol-2-yn-N-(3.4.5-trimethoxyphenvn-2-pyrimidineamine from 3,4,5-(trimethoxyphenyl)guanidine nitrate (1 .72g, 6. Ommol), 1 - (benzothiazol-2-yl)-3-dimethylamino-2-propen-1 -one (1 .39g, 6. Ommol) and sodium hydroxide (270mg, 6.6mmol) to give the title compound (420mg) as a yellow solid m.p. 182-183°. MS m/z 395 (M+H)+.
- EXAMPLE 23 4-(2-Pyridy ⁇ -N-. ' 3.4.5-trimethoxy p heny ⁇ -2-pyrimidineamine from 3,4,5-(trimethoxyphenyl)guanidine nitrate (1 .99g, 6.91 mmol), 3- dimethylamino-1 -(2-pyridyl)-2-propen-1 -one (1 .22g, 6.91 mmol) and sodium hydroxide (276mg, 6.9mmol) to give the title compound (158mg) as a yellow solid m.p. 185°. MS m/z 339 (M+H) + .
- EXAMPLE 26 4-(5-Thiazolv ⁇ -N- ( 3.4.5-trimethoxyphenyl)-2-pyrimidineamine from 3,4,5-(trimethoxyphenyl)guanidine nitrate (634mg, 2.2mmol), 3- dimethylamino-1 -(5-thiazolyl)-2-propen-1 -one (330g, 1 .81 mmol) and sodium hydroxide (88mg, 2.2mmol) to give the title compound (42mg) as a yellow solid m.p. 171°. MS m/z 345 (M+H) + .
- EXAMPLE 27 4-f4-Cvano p henvn-N-r3.4.5-trimetho ⁇ yp henyn-2-pyrimidineamine from 3,4,5-(trimethoxyphenyl)guanidine nitrate (17.0g, 59. Ommol), 1 -(4- cyanophenyl)-3-dimethylamino-2-propen-1 -one (11.82g, 58. Ommol) and sodium hydroxide (2.36mg, 59. Ommol) to give the title compound (11.66g) as a green solid m.p. 183°. MS m/z 363 (M+H) + .
- EXAMPLE 34 4-(4-Bromophenyl)-N-(3.4.5-trimetho ⁇ yphenyn-2-pyrimidineamine from 3,4,5-(t ⁇ methoxyphenyl)guan ⁇ d ⁇ ne nitrate (2.26g, 7.80mmol), 1 -(4- bromophenyl)-3-d ⁇ methylam ⁇ no-2-propen-1 -one (2.0g, 7.80mmol) and sodium hydroxide (346mg, 8.60mmol) to give the title compound (1 .0g) as a green solid m.p. 179°. MS m/z 416 (M+H)+.
- EXAMPLE 35 4-f2-Chloropyridin-5-vn-N-(3.4.5-trimethoxyphenvn-2-pyrimidine- amine from 3,4,5-(t ⁇ methoxyphenyl)guanidine nitrate (16.42g, 22.3mmol), 1 -(2- chloropy ⁇ d ⁇ n-5-yl)-3-dimethylam ⁇ no-2-propen-1 -one (4.70g, 22.3mmol) and sodium hydroxide (895mg) to give the title compound (1 .43g) as a yellow solid m.p. 191 -192°. MS m/z 373.2 (M+H)+.
- Example 7 The compound of Example 7 (400mg, 0.78mmol) was suspended in ethanol (5ml) and 4M sodium hydroxide (5ml) and heated at reflux for 4h.
- EXAMPLE 39 4- ⁇ 4-Aminopheny ⁇ -N- «3.4.5-trimethoxyphenv ⁇ -2-pyrimidineamine from the compound of Example 12 (800mg, 2.09mmoi), ammonium formate (660mg, 10.5mmol) and 10% palladium on carbon (80mg) to give the title compound (253mg) as a yellow solid m.p. 195°. MS m/z 353 (M+H) + .
- EXAMPLE 40 4-(3-Aminophenyh-N-(3.4.5-trimetho ⁇ yphenyn-2-pyrimidineamine from the compound of Example 1 1 (150mg, 0.39mmol), ammonium formate (150mg, 2.38mmol) and 10% palladium on carbon (100mg) to give the title compound (120mq) as a vellow solid m p. 166-167° MS m/z 353 (M+H) + .
- EXAMPLE 41 4- ( 3-Acetamidophenv ⁇ -N- ( 3.4.5-trimethoxyphenyl)-2-pyrimidineamine
- acetyl chloride 0.06ml, 0.78mmol
- Examples 42-44 were prepared in a similar manner to the compound of Example 41 : EXAMPLE 42 4- ( 4-Acetamidophenyh-N- (' 3.4.5-trimethoxyphenyl)-2-pyrimidineamine from the compound of Example 39 (300mg, 0.85mmol), triethylamine (0.13ml, 0.94mmol) and acetyl chloride (0.07ml, 0.94mmol) to give the title compound (178mg) as a yellow solid m.p. 239°. MS m/z 395 (M+H) + .
- Example 45 The compound of Example 45 (500mg, 0.9mmol) was suspended in ethanol (30ml) containing hydrazine monohydrate (0.14ml, 2.8mmol) and the resulting mixture heated at reflux for 18h. On cooling the resulting precipitate was filtered off and the filtrate concentrated under reduced pressure. The residue was suspended in CH2CI2 (30ml), extracted with 2N hydrochloric acid (2x30ml) Combined acid layers were taken to pH 1 1 with 6N NaOH and extracted with CH CI (3x30ml), the organic layers were dried (MgS04), and concentrated under reduced pressure. The residue was dissolved in ethanol (10ml) and the solution saturated with HCl (g).
- the compound was prepared in a manner analogous to the preparation of the compound of Example 48 from the compound of Example 50 (830mg, 1.54mmol) and hydrazine monohydrate (0.23ml, 4.62mmol) to give the title compound (63m ⁇ ) as a white solid m.p. 161 -162°. MS m/z 41 1 (M+H) + .
- the compound was prepared in a manner analogous to the preparation of the compound of Example 47 from the compound of Example 49 (250mg, 0.71 mmol), ethylene carbonate (70mg, 6.78mmol) and 60% sodium hydride (dispersion in oil) (30mg, 0.78mmol) to give the title compound (140mg) as a yellow solid m.p 145-146°. MS m/z 398 (M+H) + .
- Example 40 The compound of Example 40 (250mg, 0.71 mmol) and 3-bromopropanol were heated at 85° in DMF for 72h. The solvent was removed under reduced pressure and the residue subjected to column chromatography [silica-ethyl acetate] to give the title compound (33mg) as a yellow solid m.p. 92-95°. MS m/z 411 (M+H) + .
- EXAMPLE 58 4- ⁇ 3-Pyridylmethvnaminophenvn-N-t3.4.5-trimetho ⁇ phenyn-2- pyrimidineamine from the compound of Example 39 (250mg, 0.71 mmol), 3-pyridine- carboxaldehyde (69mg, 0.65mmol), sodium triacetoxyborohydride (226mg, 1.67mmol) and acetic acid (0.1 ml) to give the title compound (134mg) as a yellow solid m.p. 189-190°. MS m/z 444 (M+H)+.
- the 3-d ⁇ methylam ⁇ no-1 -(1 -oxopyr ⁇ d-4-yl)-2-propen-1 -one used as starting material was prepared by heating a solution of 4-acetylpy ⁇ d ⁇ ne-N-ox ⁇ de (2.5g, 18.2mmol) in dimethylformamide diethylacetal (30ml) at reflux for 0 5h On cooling the resulting solid was collected and washed with diethyl ether to give the desired product (3.18g) as an orange solid m p 181 °
- the 4-acetylpy ⁇ d ⁇ ne-N-ox ⁇ de was prepared by treating a solution of 4- acetylpyridme (3.0g, 24 8mmol) in CH 2 CI 2 with 3-chloro-peroxybenzo ⁇ c acid [Aldrich 57-86%] (8 4g) at room temperature for 12 h The reaction was filtered, the filtrate concentrated under reduced pressure and the resulting residue subjected to column chromatography [silica 10% methanol-ethyl acetate] to give the desired product (3.2g) as a white solid m.p. 101 ° EXAMPLE 62
- Example 35 The compound of Example 35 (200mg, 0.54mmol) and 3-am ⁇ no-1 - propanol (1 .0ml, 13.05mmol) were heated at 100° for 3.5h. On cooling the reaction was concentrated under reduced pressure, water (15ml) added and the resulting precipitate collected. After washing with water, drying under vacuum and recrystallisaiton from ethanol the title compound (105mg) was obtained as a yellow solid m.p. 168-160°.
- EXAMPLE 72 4-(2-f1-Benzylpiperid-4-ylamino)pyridin-5-y ⁇ -N- ⁇ 3.4.5-trimethoxy- phenyl)-2-pyrimidineamine from the compound of Example 35 (500mg, 1.35mmol) and 4-am ⁇ no-1 - benzylpiperidine (514mg, 2.7mmol) to give the title compound (370mg) as a yellow solid m.p. 113-114°. MS m/z 527 (M+H)+. EXAMPLE 73
- Example 63 In a manner analogous to Example 63 from the compound of Example 35 (500mg) and N,N'-dimethyl-1 ,3-propanediamine (1 .62ml. 13. Ommol) to give the title com p ound ( 31 m ⁇ ) as a vellow solid, m.p. 103°. MS m/z 439 (M+H) + .
- EXAMPLE 79 4- ( 2-f2-Diethylaminoethyl(methv ⁇ amino p yridin-5-v0-N-(3.4.5- trimethoxyphenvn-2-pyrimidine from the compound of Example 35 (300mg, 0.81 mmol) and N.N-d ⁇ ethyl-N'- methylethylenediamme (316mg, 2.43mmol) to give the title compound
- EXAMPLE 84 4-(2-(4-Aminobutylamino ) pyridin-5-yl)-N-(3.4.5-trimethoxyphenyl)-2- pyrimidineamine from the compound of Example 35 (300mg, 0.81 mmol) and 1 ,4-butane- diamine (705mg, 8. Ommol) as a yellow solid m.p. 209-201 °.
- EXAMPLE 85 4-(2-(2-Diethylaminoethylamino)pyridin-5-yl)-N-(3.4.5-trimethoxy- phenyl)-2-pyrimidineamine from the compound of Example 35 (300mg, 0.81 mmol) and N,N-diethyl- ethylenediamine (282mg, 2.43mmol) to give the title compound (50mg) as a yellow solid m.p. 67°. MS m/z 453 (M+H)+.
- Examples 90-110 were prepared in a similar manner to the compound of Example 89 using the starting material shown.
- the pyrimidineamine starting material was prepared from the available compounds shown in a similar manner to the pyrimidineamine starting material of Example 89:
- EXAMPLE 90 N4-(4-(2-Hvdroxyethoxy)phenvn-N2-(3.4.5-trimethoxyphenyn2.4- pyrimidineamine from 2-chloro-N-(4-(2-hydroxyethoxy)phenyl)-4-pyrimidineamine (187mg, 0.70mmol) and 3,4,5-trimethoxyaniline (146mg, O. ⁇ mmol) to give the title compound (18mg) as a colourless solid m.p.
- the pyrimidineamine starting material was prepared from 4-(2-hydroxy- ethoxy)aniline (481 mg, 3.14mmol) 2,4-dichloropyrimidine (468mg, 3.14mmol) and triethylamine (0.46ml, 3.25mmol) to give the desired product as a yellow solid m.p. 169°. MS m/z 266(M+H)+.
- the pyrimidineamine starting material was prepared from 3,4- methylenedioxyaniiine (219mg, 1.60mmol) 2,4-dichloropyrimidine (250mg, 1.60mmol) and triethylamine (0.25ml, 1 .80mmol) to give the desired product (215mg) as a buff solid m.p. 148°. MS m/z 250 (M+H)+.
- the pyrimidineamine starting material was prepared from meta-anisidme (0.18mg, 1 .6mmol), 2,4-dichloropyr ⁇ m ⁇ d ⁇ ne (250mg, 1 .6mmol) and triethylamine (0.25mg, 1.8mmol) to give the desired product (200mg) as a white solid m.p. 107°. MS m/z 236 (M+H) + .
- the pyrimidineamine starting material was prepared from 2-(4-am ⁇ no- phenyl)ethanol (219mg, 1.6mmol) 2,4-d ⁇ chloropyr ⁇ m ⁇ d ⁇ ne (250mg, 1.6mmol) and triethylamine (0.25ml, 1.8mmol) to give the desired product (289mg) as an orange solid m.p. 163°.
- the pyrimidineamine starting material was prepared from N,N-d ⁇ ethyl-1 ,4- phenyldiamine (263mg, 1.6mmol), 2,4-d ⁇ chloropyr ⁇ m ⁇ d ⁇ ne (250mg, 1.6mmol) and triethylamine (0.25ml, L ⁇ mmol) to give the desired prdocut (410mg) as a green solid m.p. 212°. MS m/z 277 (M+H).+ EXAMPLE 95
- the pyrimidineamine starting material was prepared (from 4-(3-hydroxy- propoxy)aniline (267mg, 1 .60mmol), 2,4-dichloropyrimidine (250mg, L ⁇ Ommol) and triethylamine (0.25ml, 1 .80mmol) to give the desired product (383mg) as a pale orange solid m.p. 181 °. MS m/z 280 (M+H) + .
- N4-(3,4-Dimethoxyphenyl)-N2-(3,4,5-trimethoxyphenyl)-2.4- pyrimidinediamine from 2-chloro-N-(3,4-dimethoxyphenyl)-4-pyrimidineamine (250mg) and 3,4,5-trimethoxyaniline (189mg, LOmmol) to give the title compound (160mg) as a light pink solid m.p. 86°. MS m/z 413 (M+H) + .
- the pyrimidineamine starting material was prepared from ami ⁇ overatrole (257mg, 1 .60mmol) , 2,4-dichloropyrimidine (2.50mg, 1 .60mmol) and triethylamine (0.25ml, 1 .80mmol) to give the desired product (357mg) as a purple solid m.p. 104° MS m/z 266 (M+H)L
- the pyrimidineamine starting material was prepared from 4-(4- methylpiperazin-1 -yl)aniline (51 1 mg, 2.67mmol), 2,4-dichloropyrimidine (398mg, 2.67 mmol) and triethylamine (I0.4ml, 2.94mmol) to give the desired product (1 10mg) as a white solid m.p. 122°.
- N4-(3.5-Dimethoxyphenvn-N2- ( 3.4.5-trimethoxyphenyn-2.4- pyrimidinediamine from 2-chloro-N-(3,5-dimethoxyphenyl)-4-pyrimidineamine ( 150mg, 0.56mmol) and 3,4,5-trimethoxyaniline (104mg, 0.56mmol) to give the title compound (162mg) as a white solid m.p. 180°. MS m/z 413 (M+H) + .
- the pyrimidineamine starting material was prepared from 3,5-dimethoxy- aniline (257mg, 1.60mmol), 2,4-dichloropyrimidine (250mg, 1.60mmol) and triethylamine (0.25ml, L ⁇ Ommol) to give the desired product (237mg) as a white solid m.p. 225°. MS m/z 266 (M+H)+.
- the pyrimidineamine starting material was prepared from 4-morpholino- aniline (285mg, 1.60mmol), 2,4-dichloropyrimidine (205mg, 1.60mmol) and triethylamine (0.25ml, L ⁇ Ommol) to give the desired product (322mg) as a white solid m.p. 221°. MS m/z 291 (M+H) + .
- the pyrimidineamine starting material was prepared from 3-trifluoro- methoxyaniline (354mg, 2.
- the pyrimidineamine starting material was prepared from 5-am ⁇ no-2- methylbenzimidazole (2147mg, 1 .68mmol), 2,4-dichloropyrimid ⁇ ne (250mg, 1 .68mmol) and triethylamine (0.25ml, L ⁇ Ommol) to give the desired product (344mg) as a pale pink solid m.p. >300°. MS m/z 260 (M+H) + .
- the pyrimidineamine starting material was prepared from N,N-d ⁇ methyl- 1 ,4-phenylenediamine (228mg, 1.6 ⁇ mmol) 2,4-dichloropr ⁇ m ⁇ d ⁇ ne (250mg,
- N4-(3-Ethoxyphenyl)-N2-(3.4.5-triemthoxyphenyn-2.4-pyrimidine- diamine from 2-chloro-N-(3-ethoxyphenyl)-4-pyrimidineamine (125mg, 0.5mmol) and 3,4,5-trimethoxyaniline (92mg, 0.5mmol) to give the title compound (157mg) as a white solid m.p. 79°. MS m/z 397 (M+H) + .
- the pyrimidineamine starting material was prepared from meta- phenetidine (0.15ml, 1 .68mmol), 2,4-dichloropyrimidine (250mg, 1.68mmol) and triethylamine (0.25ml, L ⁇ Ommol) to give the desired product (125mg) as a cream solid m.p. 97°.
- the pyrimidineamine starting material was prepared from para-anisidme (616mg, 5 Ommol), 2,4-d ⁇ chloropy ⁇ m ⁇ d ⁇ ne (745mg, 5. Ommol) and triethyl ⁇ amine (0 77ml, 5.5mmol) to give the desired compound (450mg) as a white solid m p. 250°.
- the pyrimidineamine starting material was prepared from 3-benzyloxy- anilme (5 Og, 25. Ommol), 2,4-d ⁇ chloropyr ⁇ m ⁇ d ⁇ ne (3.7g, 25 Ommol) and triethylamine (3. ⁇ ml, 27.5mmol) to give the desired compound (4.95g) as a white solid m.p. 1 19° MS m/z 312 (M+H) +
- the pyrimidineamine starting material was prepared from 5-am ⁇ no-1- phenylsulphonylmdole (LOg, 3.9mmol), 2,4-d ⁇ chloropy ⁇ m ⁇ d ⁇ ne (577mg, 3.9mmol) and triethylamine (0.61 ml) to give the desired product (1 20g) as an orange solid m.p 156° MS m/z 335 (M+H)+.
- EXAMPLE 110 N4-Cyclohexyl-N2- ⁇ 3.4.5-trimetho ⁇ yphenvn-2.4-pyrimidinediamine from 2-chloro-N-cyclohexylamino-4-pyrimidineamine (200mg, 0.9mmol) and 3,4,5-trimethoxyaniiine (173mg, O. ⁇ mmol) to give the title compound (173mg) as a white solid m.p. 160-161 °.
- the pyrimidineamine starting material was prepared from 4-am ⁇ no- 1 - benzyipiperidine (0.7ml, 3.4mmol), 2,4-dichloropyrimidine (500mg, 3.4mmol) and triethylamine (0.5ml, 3.7mmol) to give the desired product (650mg) as a white solid m.p. 136°. MS m/z 303 (M+H)+.
- the pyrimidineanine starting material was prepared from benzylamine (3.67ml, 33.56mmol), 2,4-dichloropyrimidine (5.0g, 33.56mmol) and triethylamine (5.14ml, 36.9mmol) to give the desired product (4.21 g) as a white solid, m.p. 135-136°. MS m/z 220 (M+H)+.
- the aniline starting material was prepared by treating a solution of 1 ,2- d ⁇ methoxy-3-(methylsulph ⁇ nyl)-5-n ⁇ trobenzene ( 1 .64g , 6.69mmol) in methanol (20ml) and concentrated hydrochloric acid (20ml) was treated with anhydrous tin (II) chloride (7.15g, 37.7mmol) and the resulting mixture refluxed for 1 .25h. On cooling to room temperature the mixture was poured into excess 1 M NaOH solution and extracted with CH CI 2 . The organic extract was dried (MgS ⁇ ) and evaporated to afford the desired product (1 .33g) as an off-white solid m.p. 106-107°. MS m/z 199 (M+H) + .
- the aniline starting material was prepared in a similar manner to the analogous aniline of Example 1 13, from 1 -chloro-2,3-dimethoxy-5- nitrobenzene (1 .08g, 5. ⁇ 2mmol), to give the desired product (0.85g) as a white solid m.p. 66-68°. MS m/z 188 (M+H). + The 1 -chloro-2,3-dimethoxy-5-nitrobenzene was prepared by heating a solution of 3-chioro-4,5-dimethoxybenzoic acid (3.50g, 16.2mmol) in glacial acetic acid (15ml) and 70% nitric acid (15ml) at 60° for i h.
- the 3-benzyloxy-4,5-d ⁇ methoxyan ⁇ l ⁇ ne was prepared by heating a solution of 1 -benzyloxy-2,3-d ⁇ methoxy-5-n ⁇ trobenzene (1 .80g, 6.23mmol) in ethanol (15ml) with saturated aqueous sodium hydrosulphite (20ml) at reflux for 2h. An additional quantity of sodium hydrosulphite (20ml) was added and reflux continued for a further 4h. The reaction mixture was reduced to a small volume then diluted with water and extracted three times with ethyl acetate.
- the 1 -benzyloxy-2,3-d ⁇ methoxy-5-n ⁇ trobenzene used as starting material was prepared by treating a solution of 1 -benzoyl-2,3-d ⁇ methoxybenzene (7.25g, 29.66mmol) in glacial acetic acid (15ml) portionwise with 70% nitric acid (2.84ml) at room temperature. After 2h, the reaction mixture was poured into ice-water and extracted with ethyl acetate. The organic phase was washed with 1 M NaOH, then brine, dried (MgS ⁇ 4 ) and evaporated.
- the 3-acetam ⁇ do-4,5-d ⁇ methoxyan ⁇ l ⁇ ne was prepared in an analogous manner to the compound of Example 38, from 1 -acetam ⁇ do-2,3- d ⁇ methoxy-5-n ⁇ trobenzene (1.65g, 6. ⁇ mmol) to afford the desired product (1.37g) as a brown solid m.p. 156-160° MS m/z 211 (M+H) + .
- the 1 -acetam ⁇ do-2,3-d ⁇ methoxy-5-n ⁇ trobenzene was prepared in an analogous manner to the nitrobenzene of Example 117 from 1 -acetam ⁇ do- 2,3-d ⁇ methoxybenzene (1.91 g, 9.6mmol) to give the desired product (1.70g) as a white solid m.p. 63°. MS m/z 241 (M+H)+.
- the 1 -acetam ⁇ do-2,3-d ⁇ methoxybenzene was prepared by treating a solution of 2,3-d ⁇ methoxyan ⁇ l ⁇ ne (1.70g, 1 1.1 mmol) in carbon tetrachloride (25ml) with methanol (0.2ml) followed by acetic anhydride (3.67g, 36. Ommol) and heating the resulting mixture at reflux for 1 h
- the cooled reaction mixture was diluted with CH 2 CI 2 , washed with water, dried (MgS ⁇ 4) and evaporated to give the desired product (2.1 1 g) as a beige solid m.p. 164-165°.
- MSm/z 196 (M+H) + MSm/z 196 (M+H) + .
- N4- ⁇ 4-(3-Aminopropoxy)phenv0-N2- (' 3.4.5-trimethoxyphen ⁇ l)-2.4- pyrimidinediamine dihydrochloride In a manner analogous to the preparation of the compound of Example 48 from N4-(4-(3-phthal ⁇ m ⁇ dopropoxy)phenyl)-N2-(3,4,5-t ⁇ methoxyphenyl)- 2,4-py ⁇ m ⁇ d ⁇ ned ⁇ am ⁇ ne (400mg, 0.72mmol) and hydrazine monohydrate (0.1 ml, 2.16mmol) to give the title compound (108mg) as a buff solid m.p. 258°.
- the py ⁇ midinediemine starting material was prepared according to the method of Example 45 from the compound of Example 120 and 3- bromopropylphthalim.de EXAMPLE 122
- the pyrimidine-4-carboxamide used as starting material was prepared by treating a solution of 4-carboxy-N-(3,4,5-trimethoxyphenyl)-2-pyrimidine- amine hydrochloride (2.0g, 5.86mmol) and triethylamine (2.0ml, 14.0mmol) in CH 2 CI 2 (40ml), cooled to -20° under a nitrogen atmosphere, with isobutylchloroformate (1.1 ml, 7.0mmol). The resulting mixture was stirred for 20min.
- N.O-dimethylhydroxylamine hydrochloride (683mg, 7.0mmol) and triethylamine (1.0ml, 7.0mmol) were added and the reaction allowed to warm to room temperature over 3h. After washing with 2M hydrochloric acid (1 x50ml) and 2M NaOH solution (1 x50ml), the reaction was dried (MgS04) and concentrated under reduced pressure. The residue was subjected to column chromatography [silica ethyl acetate] to give the desired product (1.02g), as a yellow oil.
- the 4-carboxy-N-(3,4,5-tr ⁇ methoxyphenyl)-2-pyr ⁇ m ⁇ d ⁇ neam ⁇ ne hydro ⁇ chloride was prepared by heating a solution of 4-cyano-N-(3,4,5- t ⁇ methoxyphenyl)-N-py ⁇ m ⁇ d ⁇ neam ⁇ ne (2.86g, 10 49mmol) in aqueous 2N NaOH (60ml) and ethanol (10ml) at reflux for 3h. On cooling the reaction mixtrure was adjusted to pH 3 with 2M hydrochloric acid, and the resulting precipitate collected and dried to give the desired product (2.7g) as an orange solid m.p. 241 °. MS m/z 306 (M+H) + .
- the 4-cyano-N-(3,4,5-t ⁇ methoxyphenyl)-2-py ⁇ m ⁇ d ⁇ neam ⁇ ne was prepared by heating a solution of 2-chloro-4-cyanopy ⁇ m ⁇ d ⁇ ne [G. Davies et al. J. Het. Chem. 1, 130-133, (1963)] (1 1 . Og, 76.6mmol), 3,4,5-t ⁇ methoxy aniline (14 4g, 79.4mmol) and triethylamine (12.0ml) in ethanol at reflux for 4h. On cooling the resulting precipitate was collected and dried to give the desired product (1 3.70 g) as a yellow solid m p. 1 65° MS m/z 287 (M+H) + .
- the 2-chloro-4-phenylsulphonamidopyr ⁇ midine was prepared by heating 2,4-dichloropyrimidine (1.42g, 9.5mmol), benzenesulphonamide (4.5g, 29. Ommol) and potassium, carbonate (3.3g, 24.0mmol) in DMA (25ml) for 0.75h). The reaction was cooled to 5°, water (20ml) added, and ad j usted to pH2.5 with 2M HCl. The resulting precipitate was collected to give the desired product (1.8g) as a light yellow solid m.p. 164° MS m/z 270 (M+H) + .
- the N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine used as starting material was prepared by treating a solution of the compound of Example 131 (600mg, 1 .6mmol) in methanol (10ml) with 2M hydrochloric acid (10ml), which was then heated at reflux for 2h. On cooling the methanol was evaporated and the aqueous solution adjusted to pH 12 with 2N aqueous NaOH. The basic solution was extracted with CH2CI2 (3x30ml), then the combined organic extracts were washed with saturated brine (1 x20ml), dried (MgS04) and concentrated under reduced pressure to give the desired product (340mg) as a light yelllow solid m.p. 89°. MS m/z 277 (M+H) + .
- the 2-chloro-4-phenylsulphanylpy ⁇ m ⁇ d ⁇ ne was prepared by treating a solution of thiophenol (4.7ml, 45.4mmoi) in THF (30ml) at 0°, with a 1 .0M solution of sodium b ⁇ s(t ⁇ methylsilyl)am ⁇ de in THF (45.4ml) and the mixture stirred for 0.5h After a thick white precipitate had formed, 2,4- dichloropy ⁇ midine (6.83g, 45.4mmol) and DMA (70ml) were added and the mixture heated at 120° for 2h.
- the starting material for the above process was obtained by treating a solution of the compound of Example 39 (250mg, 0.71 mmol) in CH 2 CI 2 (10ml) with N-FMOCglycyl chloride (337mg, 1 07mmol) and 5% aqueous Na 2 C0 3 solution (8ml). After the mixture had been stirred for 1 h at room temperature, the aqueous phase was discarded and the organic Iayer dried (MgS04) and evaporated. The residue was subjected to column chromatography [silica 10% methanol-CH 2 CI 2 ] to give the desired product (235mg) as an off-white solid, m.p. 102° (decomp.).
- am e starting material for this reaction was prepared from the following: 4-Chloro-6-methyl-N- ⁇ 3.4.5-trimethoxyphenyhpyrimidine-2-amine (b)
- the py ⁇ midinone starting material for this reaction was prepared as follows:
- the tyrosine kinase activity of p56 lck was determined using a RR-src peptide (RRLIEDNEYTARG) and [ ⁇ -33p]ATP as substrates. Quantitation of the 33 P-phosphorylated peptide formed by the action of p56 lck was achieved using an adaption of the method of Geissler et al (J. Biol. Chem.
- p59i ⁇ 0 kinase assay Compounds of the invention were assayed for p ⁇ inhibitory activity in a similar manner to the p56 i k assay, using human pS ⁇ ty 1"1 .
- the tyrosine kinase activity of the EGF receptor (EGFr) was determined using a similar methodology to the p56 lck kinase assay, except that the
- RR-src peptide was replaced by a peptide substrate for EGFr obtained from Amersham International pic (Little Chalfont, UK) and used at the manufacturers recommended concentration IC50 values for each test inhibitor were determined as described previously in the p56 lck assay.
- the tyrosine kinase activity of ZAP-70 was determined using a capture assay based on that employed above for p56 lck
- the RR-src peptide was replaced with polyGlu-Tyr (Sigma, Poole, UK) at a final concentration of 17 ⁇ g/ml.
- trichloroacetic acid 10% was employed as the wash reagent instead of acetic acid and a final wash in absolute ethanol was also performed before scintillation counting IC50 values for each test inhibitor were determined as desc ⁇ bed above in the p56 lck assay
- PKC Protein kinase C assay Inhibitor activity against protein kinase C (PKC) was determined using PKC obtained from Sigma Chemical Company (Poole, UK) and a commercially available assay system (Amersham International pic, Little Chalfont, UK). Briefly, PKC catalyses the transfer of the ⁇ -phosphate (32p) of ATP to the threonine group on a peptide specific for PKC Phosphorylated peptide is bound to phosphocellulose paper, subsequently quantified by scintillation counting and IC50 values determined as before
- compounds according to the invention inhibit the protein kinase p56 lck , p59 f y n , ZAP- 70 or protein kinase C at concentrations at which they have little or no effect on the remaining kinases, including EGFr kinase and Csk kinase
- the compounds of Example 96 and 103 have IC50 values in the p56 lck assay of 215nM and 40nM respectively
- the compounds are also active against p59 f y n but have IC50 values at least 10x greater against the remaining kinases described above.
- the compounds of Example 64 and 66 have IC50 values in the ZAP-70 assay of 124nM and 68nM respectively.
- the compounds are also active in the protein kinase C assay, but have IC 50 values at least 10x greater against the remaining kinases.
- the compounds of Examples 48 and 81 have IC 50 values in the protein kinase C assay of 22nM and 92nM respectively, but have IC 50 values at least 10x greater against the remaining kinases.
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9523675.8A GB9523675D0 (en) | 1995-11-20 | 1995-11-20 | Chemical compounds |
GB9523675 | 1995-11-20 | ||
PCT/GB1996/002854 WO1997019065A1 (en) | 1995-11-20 | 1996-11-20 | Substituted 2-anilinopyrimidines useful as protein kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0862560A1 true EP0862560A1 (en) | 1998-09-09 |
EP0862560B1 EP0862560B1 (en) | 2003-04-02 |
Family
ID=10784140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96939171A Expired - Lifetime EP0862560B1 (en) | 1995-11-20 | 1996-11-20 | Substituted 2-anilinopyrimidines useful as protein kinase inhibitors |
Country Status (7)
Country | Link |
---|---|
US (2) | US5958935A (en) |
EP (1) | EP0862560B1 (en) |
AU (1) | AU7631496A (en) |
DE (1) | DE69627179T2 (en) |
ES (1) | ES2195020T3 (en) |
GB (1) | GB9523675D0 (en) |
WO (1) | WO1997019065A1 (en) |
Families Citing this family (367)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9619284D0 (en) * | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
AU4563197A (en) * | 1996-10-01 | 1998-04-24 | Celltech Therapeutics Limited | Pharmaceutical products containing protein-tyrosine kinase inhibitors and anti-cd4 antibodies |
GB9622363D0 (en) * | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
US6608060B1 (en) | 1996-12-18 | 2003-08-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
US6147080A (en) * | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
US5945418A (en) * | 1996-12-18 | 1999-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
JP2001507349A (en) * | 1996-12-23 | 2001-06-05 | セルテック セラピューティックス リミテッド | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
GB9705361D0 (en) * | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
AU1507199A (en) | 1997-12-15 | 1999-07-05 | Yamanouchi Pharmaceutical Co., Ltd. | Novel pyrimidine-5-carboxamide derivatives |
ES2361146T3 (en) | 1998-03-27 | 2011-06-14 | Janssen Pharmaceutica Nv | DERIVATIVES OF HIV INHIBITATORY PYRAMIDINE. |
WO1999063821A1 (en) | 1998-06-10 | 1999-12-16 | Basf Aktiengesellschaft | Use of 2-(n-phenylamino)pyrimidines as fungicides, and novel 2-(n-phenylamino)pyrimidines |
EP1119349B1 (en) * | 1998-08-18 | 2008-07-02 | The Regents Of The University Of California | Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs |
US7354894B2 (en) | 1998-08-18 | 2008-04-08 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
US6846799B1 (en) | 1998-08-18 | 2005-01-25 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
JP2002523498A (en) | 1998-08-29 | 2002-07-30 | アストラゼネカ・アクチエボラーグ | Pyrimidine compounds |
ES2274634T3 (en) | 1998-08-29 | 2007-05-16 | Astrazeneca Ab | PIRIMIDINE COMPOUNDS. |
IL143023A0 (en) | 1998-11-10 | 2002-04-21 | Janssen Pharmaceutica Nv | Hiv replication inhibiting pyrimidines |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
US6797706B1 (en) | 1999-06-09 | 2004-09-28 | Yamanouchi Pharmaceutical Co., Ltd. | Heterocyclecarboxamide derivative |
JP2003503354A (en) | 1999-06-30 | 2003-01-28 | メルク エンド カムパニー インコーポレーテッド | SRC kinase inhibitor compounds |
US6498165B1 (en) | 1999-06-30 | 2002-12-24 | Merck & Co., Inc. | Src kinase inhibitor compounds |
WO2001000207A1 (en) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
US6432979B1 (en) | 1999-08-12 | 2002-08-13 | American Cyanamid Company | Method of treating or inhibiting colonic polyps and colorectal cancer |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
PL355639A1 (en) | 1999-09-10 | 2004-05-04 | Merck & Co, Inc. | Tyrosine kinase inhibitors |
DE19945982A1 (en) * | 1999-09-24 | 2001-03-29 | Knoll Ag | Velocity-determined particles |
PT1225874E (en) | 1999-09-24 | 2006-06-30 | Janssen Pharmaceutica Nv | ANTIVIRAL COMPOSITIONS. |
DE60039059D1 (en) * | 1999-10-07 | 2008-07-10 | Amgen Inc | TRIAZINE KINASE INHIBITORS |
GB9924862D0 (en) * | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
US7101869B2 (en) | 1999-11-30 | 2006-09-05 | Pfizer Inc. | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
EE200200275A (en) * | 1999-11-30 | 2003-10-15 | Pfizer Products Inc. | 2,4-Diaminopyrimidine compounds used as immunosuppressants |
US20020002169A1 (en) | 1999-12-08 | 2002-01-03 | Griffin John H. | Protein kinase inhibitors |
EE200200357A (en) | 1999-12-23 | 2003-10-15 | Pfizer Products Inc. | Pharmaceutical compositions providing increased concentrations of the drug substance |
EP1242385B1 (en) * | 1999-12-28 | 2009-11-25 | Pharmacopeia, Inc. | Cytokine, especially tnf-alpha, inhibitors |
AU3704101A (en) * | 2000-02-17 | 2001-08-27 | Amgen Inc | Kinase inhibitors |
GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004888D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
IL151946A0 (en) * | 2000-03-29 | 2003-04-10 | Cyclacel Ltd | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders |
ES2559273T3 (en) | 2000-05-08 | 2016-02-11 | Janssen Pharmaceutica Nv | Pyrimidine prodrugs that inhibit HIV replication |
US7276510B2 (en) | 2000-05-08 | 2007-10-02 | Janssen Pharmaceutica, Inc. | HIV replication inhibitors |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
US7521463B2 (en) | 2000-07-31 | 2009-04-21 | University Of Maryland, Baltimore | Immunomodulatory compounds |
GB0021726D0 (en) | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
EP1317452B1 (en) | 2000-09-15 | 2006-05-17 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
PL214667B1 (en) | 2000-12-21 | 2013-08-30 | Glaxo Group Ltd | Pyrimidineamines as angiogenesis modulators |
US6653301B2 (en) | 2000-12-21 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
SE0100569D0 (en) * | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | New compounds |
CN100415744C (en) * | 2001-02-20 | 2008-09-03 | 阿斯特拉曾尼卡有限公司 | 2-arylamino-pyrimidines for the treatment of GSK3-related disorders |
WO2002068409A1 (en) * | 2001-02-23 | 2002-09-06 | Merck & Co., Inc. | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists |
GB0107901D0 (en) * | 2001-03-29 | 2001-05-23 | Cyclacel Ltd | Anti-cancer compounds |
MXPA03008888A (en) * | 2001-03-29 | 2005-03-07 | Vertex Pharma | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases. |
US6881737B2 (en) | 2001-04-11 | 2005-04-19 | Amgen Inc. | Substituted triazinyl acrylamide derivatives and methods of use |
US6864255B2 (en) | 2001-04-11 | 2005-03-08 | Amgen Inc. | Substituted triazinyl amide derivatives and methods of use |
DE10127581A1 (en) * | 2001-05-29 | 2003-01-02 | Schering Ag | New 2-anilino-pyrimidine derivatives, are potent cyclin dependent kinase inhibitors, useful e.g. for treating cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections |
MXPA03010810A (en) * | 2001-05-29 | 2004-03-22 | Schering Ag | Cdk inhibiting pyrimidines, production thereof and their use as medicaments. |
GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
MXPA03010961A (en) | 2001-05-31 | 2004-02-27 | Vertex Pharma | Thiazole compounds useful as inhibitors of protein kinases. |
ATE339418T1 (en) * | 2001-06-01 | 2006-10-15 | Vertex Pharma | THIAZOLE COMPOUNDS THAT ARE SUITABLE AS INHIBITORS OF PROTEIN KINASES |
ATE432929T1 (en) * | 2001-06-15 | 2009-06-15 | Vertex Pharma | 5-(2-AMINOPYRIMIDINE-4-YL)BENZISOXAZOLE AS A PROTEIN KINASE INHIBITOR |
WO2002102783A1 (en) * | 2001-06-19 | 2002-12-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
CA2450562A1 (en) | 2001-06-22 | 2003-01-03 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2003002109A2 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating autoimmune diseases |
ATE343415T1 (en) * | 2001-06-29 | 2006-11-15 | Ab Science | THE USE OF C-KIT INHIBITORS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE |
CA2452366A1 (en) * | 2001-06-29 | 2003-01-16 | Ab Science | Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
WO2003002106A2 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitions for treating allergic diseases |
EP1401415B1 (en) * | 2001-06-29 | 2006-06-21 | AB Science | Use of n-phenyl-2-pyrimidine-amine derivatives for treating inflammatory diseases |
EP1434991B1 (en) * | 2001-06-29 | 2007-10-17 | AB Science | New potent, selective and non toxic c-kit inhibitors |
US8101629B2 (en) * | 2001-08-13 | 2012-01-24 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
JO3429B1 (en) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | Hiv inhibiting pyrimidines derivatives |
US7638522B2 (en) * | 2001-08-13 | 2009-12-29 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
US6939874B2 (en) * | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
US7115617B2 (en) * | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
WO2003020702A2 (en) | 2001-08-31 | 2003-03-13 | The Rockefeller University | Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain |
ATE404202T1 (en) * | 2001-09-20 | 2008-08-15 | Ab Science | THE USE OF POTENT, SELECTIVE AND NONTOXIC C-KITE INHIBITORS FOR THE TREATMENT OF INTERSTITIAL CYTRAL INFLAMMATION |
CA2461182A1 (en) * | 2001-09-20 | 2003-05-01 | Ab Science | Use of tyrosine kinase inhibitors for promoting hair growth |
WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
WO2003026664A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Corporation | 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
EP1760082A1 (en) * | 2001-09-28 | 2007-03-07 | Cyclacel Limited | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as anti-proliferative compounds |
WO2003032997A1 (en) | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidine derivatives, pharmaceutical agent containing said compounds, use and method for making same |
EP1453516A2 (en) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Novel tri-substituted pyrimidines, method for production and use thereof as medicament |
US7514445B2 (en) * | 2001-11-01 | 2009-04-07 | Janssen Pharmaceutica N.V. | Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors) |
HUP0402330A3 (en) * | 2001-11-01 | 2010-03-29 | Janssen Pharmaceutica Nv | Amide derivatives as glycogen synthase kinase 3-beta inhibitors, process for producing them, pharmaceutical compositions containing them and use thereof |
MXPA04005027A (en) * | 2001-11-28 | 2004-08-11 | Btg Int Ltd | Preventives or remedies for alzheimer's disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds. |
SE0104140D0 (en) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
WO2003055489A1 (en) * | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
EP1470121B1 (en) * | 2002-01-23 | 2012-07-11 | Bayer HealthCare LLC | Pyrimidine derivatives as rho-kinase inhibitors |
TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
AR038368A1 (en) | 2002-02-01 | 2005-01-12 | Novartis Ag | N-PYRIMIDIN-2-IL-AMINAS SUBSTITUTED COMPOUNDS AS IGE INHIBITORS, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH COMPOUNDS FOR THE PREPARATION OF A MEDICINAL PRODUCT |
AU2003209077A1 (en) | 2002-02-08 | 2003-09-02 | Smithkline Beecham Corporation | Pyrimidine compounds |
EP1478380B1 (en) * | 2002-02-27 | 2006-08-02 | AB Science | Use of tyrosine kinase inhibitors for treating cns disorders |
WO2003074515A1 (en) * | 2002-03-01 | 2003-09-12 | Smithkline Beecham Corporation | Diamino-pyrimidines and their use as angiogenesis inhibitors |
WO2003076434A1 (en) | 2002-03-09 | 2003-09-18 | Astrazeneca Ab | 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity |
GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0206215D0 (en) * | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
WO2003095448A1 (en) * | 2002-05-06 | 2003-11-20 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
WO2004000318A2 (en) * | 2002-06-21 | 2003-12-31 | Cellular Genomics, Inc. | Certain amino-substituted monocycles as kinase modulators |
AU2003249212C1 (en) * | 2002-07-15 | 2011-10-27 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
DE10233737A1 (en) * | 2002-07-24 | 2004-02-05 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Use of modulators of the signal transduction pathway via the protein kinase Fyn for the treatment of tumor diseases |
IL166241A0 (en) * | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
SI1534286T1 (en) | 2002-07-29 | 2010-04-30 | Rigel Pharmaceuticals Inc | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
KR101297924B1 (en) * | 2002-07-29 | 2013-08-20 | 리겔 파마슈티칼스, 인크. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
CA2494061C (en) * | 2002-07-31 | 2011-06-14 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
CN1319968C (en) | 2002-08-02 | 2007-06-06 | 沃泰克斯药物股份有限公司 | Compositions useful as inhibitors of GSK-3 |
KR101140785B1 (en) * | 2002-08-09 | 2012-05-03 | 얀센 파마슈티카 엔.브이. | Processes for the preparation of 4-[[4-[[4-2-cyanoethenyl-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
JP4741948B2 (en) | 2002-08-14 | 2011-08-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | Protein kinase inhibitors and their use |
DE10239042A1 (en) * | 2002-08-21 | 2004-03-04 | Schering Ag | New fused macrocyclic pyrimidine derivatives, useful as e.g. cyclin-dependent kinase inhibitors for treating e.g. cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections |
EP1551824B1 (en) * | 2002-10-09 | 2007-12-12 | Critical Outcome Technologies, Inc. | Protein tyrosine kinase inhibitors |
EP1562911B1 (en) | 2002-11-01 | 2010-01-06 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of jak and other protein kinases |
CA2506773A1 (en) * | 2002-11-04 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Heteroaryl-pyramidine derivatives as jak inhibitors |
CA2507406A1 (en) | 2002-11-05 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of jak and other protein kinases |
GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
WO2004058749A1 (en) * | 2002-12-18 | 2004-07-15 | Vertex Pharmaceuticals Incorporated | Benzisoxazole derivatives useful as inhibitors of protein kinases |
GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
AP2385A (en) * | 2002-12-20 | 2012-03-23 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth. |
US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
ATE440087T1 (en) | 2003-01-30 | 2009-09-15 | Boehringer Ingelheim Pharma | 2,4-DIAMINOPYRIMIDENE DERIVATIVES THAT ARE SUITABLE AS INHIBITORS OF PKC-THETA |
EA011164B1 (en) | 2003-02-07 | 2009-02-27 | Янссен Фармацевтика Н. В. | Pyrimidine derivatives for the prevention of hiv infection |
JP4634367B2 (en) * | 2003-02-20 | 2011-02-16 | スミスクライン ビーチャム コーポレーション | Pyrimidine compounds |
GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
JP2006522125A (en) * | 2003-03-25 | 2006-09-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | Thiazoles useful as protein kinase inhibitors |
GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
EP1648875A1 (en) * | 2003-07-30 | 2006-04-26 | Cyclacel Limited | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
DK1656372T3 (en) | 2003-07-30 | 2013-07-01 | Rigel Pharmaceuticals Inc | 2,4-PYRIMIDINE DIAMINE COMPOUNDS FOR USING TREATMENT OR PREVENTION OF AUTO-IMMUNE DISEASES |
ES2365223T3 (en) * | 2003-08-07 | 2011-09-26 | Rigel Pharmaceuticals, Inc. | 2,4-PYRIMIDINDIAMINE COMPOUNDS AND USES AS ANTIPROLIFERATIVE AGENTS. |
MXPA06001759A (en) * | 2003-08-15 | 2006-05-12 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders. |
GB0321710D0 (en) * | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
CA2538413A1 (en) * | 2003-09-18 | 2005-03-24 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
EP2213661B1 (en) * | 2003-09-26 | 2011-07-20 | Exelixis Inc. | c-Met Modulators and Methods of Use |
CA2540828A1 (en) * | 2003-09-30 | 2005-04-14 | Scios Inc. | Heterocyclic amides and sulfonamides |
JP2007510626A (en) | 2003-10-17 | 2007-04-26 | アストラゼネカ アクチボラグ | 4- (Pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer |
GB0324599D0 (en) * | 2003-10-21 | 2003-11-26 | Cyclacel Ltd | Compound |
WO2005042525A1 (en) * | 2003-10-21 | 2005-05-12 | Cyclacel Limited | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy |
SG139747A1 (en) | 2003-11-18 | 2008-02-29 | Novartis Ag | Inhibitors of the mutant form of kit |
DK1689715T3 (en) * | 2003-12-03 | 2011-05-23 | Ym Biosciences Australia Pty | tubulin inhibitors |
TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
GB0402653D0 (en) * | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
MXPA06013165A (en) | 2004-05-14 | 2007-02-13 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth. |
EP1751142A1 (en) | 2004-05-14 | 2007-02-14 | Pfizer Products Incorporated | Pyrimidines derivatives for the treatment of abnormal cell growth |
CA2566477A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
EP1763514A2 (en) | 2004-05-18 | 2007-03-21 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
EP1598343A1 (en) * | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine derivatives as PLK inhibitors |
GB0411791D0 (en) * | 2004-05-26 | 2004-06-30 | Cyclacel Ltd | Compounds |
US7601714B2 (en) | 2004-07-08 | 2009-10-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pyrimidine derivatives useful as inhibitors of PKC-theta |
AU2005276231A1 (en) | 2004-08-27 | 2006-03-02 | Cyclacel Limited | Purine and pyrimidine CDK inhibitors and their use for the treatment of autoimmune diseases |
US7662837B2 (en) * | 2004-10-22 | 2010-02-16 | Janssen Pharmaceutica N.V. | Inhibitors of c-fms kinase |
MX2007004784A (en) * | 2004-10-22 | 2007-09-11 | Johnson & Johnson | Inhibitors of c-fms kinase. |
US7645755B2 (en) * | 2004-10-22 | 2010-01-12 | Janssen Pharmaceutical N.V. | Inhibitors of c-fms kinase |
ES2380550T3 (en) | 2004-11-24 | 2012-05-16 | Rigel Pharmaceuticals, Inc. | Spiro-2,4-pyrimidinediamine compounds and their uses |
CA2590939C (en) | 2004-12-17 | 2011-10-18 | Amgen Inc. | Aminopyrimidine compounds and methods of use |
GB0500492D0 (en) * | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
DK1853588T3 (en) | 2005-02-16 | 2008-09-15 | Astrazeneca Ab | Chemical compounds |
US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
AU2006242311B2 (en) | 2005-05-02 | 2010-03-04 | Novartis Ag | Use of pyrimidylamimobenzamide derivatives for the treatment of systematic mastocytosis |
US20060270694A1 (en) * | 2005-05-03 | 2006-11-30 | Rigel Pharmaceuticals, Inc. | JAK kinase inhibitors and their uses |
BRPI0610184A2 (en) | 2005-05-16 | 2012-09-25 | Astrazeneca Ab | compound, pharmaceutically acceptable salt of a compound, process for preparing a compound or a pharmaceutically acceptable salt thereof, use of a compound or a pharmaceutically acceptable salt thereof, methods for inhibiting trk activity, for cancer treatment or prophylaxis and for producing an antiproliferative effect on a warm-blooded animal, and, pharmaceutical composition |
CA2611312C (en) | 2005-06-06 | 2013-12-03 | Intra-Cellular Therapies, Inc. | Organic compounds |
KR101312225B1 (en) | 2005-06-08 | 2013-09-26 | 리겔 파마슈티칼스, 인크. | Compositions and methods for inhibition of the jak pathway |
US20070203161A1 (en) * | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US20060281788A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
WO2007025103A2 (en) * | 2005-08-23 | 2007-03-01 | Intra-Cellular Therapies, Inc. | Organic compounds for treating reduced dopamine receptor signalling activity |
US7678363B2 (en) * | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
US7745428B2 (en) | 2005-09-30 | 2010-06-29 | Astrazeneca Ab | Imidazo[1,2-A]pyridine having anti-cell-proliferation activity |
GB0520955D0 (en) * | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
GB0520958D0 (en) * | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
CA2626375A1 (en) | 2005-10-28 | 2007-05-03 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer |
JP5191391B2 (en) * | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | Bi-aryl meta-pyrimidine inhibitors of kinases |
US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
WO2007053776A1 (en) * | 2005-11-03 | 2007-05-10 | Sgx Pharmaceuticals, Inc. | Pyrimidinyl-thiophene kinase modulators |
ES2533241T3 (en) | 2005-11-03 | 2015-04-08 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
WO2007056151A2 (en) * | 2005-11-03 | 2007-05-18 | Irm Llc | Protein kinase inhbitors |
US7713987B2 (en) * | 2005-12-06 | 2010-05-11 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2,4-diamines and their uses |
CA2633740A1 (en) * | 2005-12-22 | 2007-06-28 | Crystalgenomics, Inc. | Aminopyrimidine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same |
KR20080110998A (en) * | 2006-01-30 | 2008-12-22 | 엑셀리시스, 인코포레이티드 | 4-aryl-2-mino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them |
DK1984357T3 (en) * | 2006-02-17 | 2014-01-13 | Rigel Pharmaceuticals Inc | 2,4-PYRIMIDINE DIAMINE COMPOUNDS FOR TREATMENT OR PREVENTION OF AUTO-IMMUNE DISEASES |
CA2642229C (en) * | 2006-02-24 | 2015-05-12 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
CA2650057C (en) | 2006-04-20 | 2014-07-29 | Janssen Pharmaceutica N.V. | Phenyl- or pyridinyl-amide as inhibitors of c-fms kinase |
PL2021335T3 (en) | 2006-04-20 | 2011-10-31 | Janssen Pharmaceutica Nv | Heterocyclic compounds as inhibitors of c-fms kinase |
US8674100B2 (en) | 2006-04-20 | 2014-03-18 | Janssen Pharmaceutica, N.V. | Inhibitors of C-FMS kinase |
US20070293494A1 (en) * | 2006-06-15 | 2007-12-20 | Djung Jane F | 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines |
KR20090023698A (en) | 2006-06-15 | 2009-03-05 | 베링거 인겔하임 인터내셔날 게엠베하 | 2-anilino-4-aminoalkyleneaminopyrimidines |
CL2007003244A1 (en) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | COMPOUNDS DERIVED FROM PIRIMIDO [5,4-D] [2] BENZAZEPINA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER. |
US8163902B2 (en) | 2006-11-21 | 2012-04-24 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US9006258B2 (en) | 2006-12-05 | 2015-04-14 | Intra-Cellular Therapies, Inc. | Method of treating female sexual dysfunction with a PDE1 inhibitor |
UA100846C2 (en) | 2006-12-08 | 2013-02-11 | Айерем Елелсі | Compounds and compositions as protein kinase inhibitors |
EP2094682A2 (en) * | 2006-12-22 | 2009-09-02 | Novartis AG | Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections |
US8138191B2 (en) | 2007-01-11 | 2012-03-20 | Critical Outcome Technologies Inc. | Inhibitor compounds and cancer treatment methods |
US8034815B2 (en) | 2007-01-11 | 2011-10-11 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
AU2008210266B2 (en) * | 2007-01-31 | 2013-09-05 | Ym Biosciences Australia Pty Ltd | Thiopyrimidine-based compounds and uses thereof |
KR101566840B1 (en) * | 2007-03-12 | 2015-11-06 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | Phenyl amino pyrimidine compounds and uses thereof |
MX2009011810A (en) | 2007-05-02 | 2010-01-14 | Vertex Pharma | Thiazoles and pyrazoles useful as kinase inhibitors. |
UA99459C2 (en) | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
CA2693594A1 (en) * | 2007-07-17 | 2009-01-22 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as pkc inhibitors |
AU2008282156B2 (en) | 2007-07-31 | 2014-07-17 | Vertex Pharmaceuticals Incorporated | Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof |
WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
JP5611826B2 (en) * | 2007-09-04 | 2014-10-22 | ザ スクリプス リサーチ インスティテュート | Substituted pyrimidinyl-amines as protein kinase inhibitors |
JO3240B1 (en) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | Inhibitors of c-fms Kinase |
JP2011032169A (en) * | 2007-12-11 | 2011-02-17 | Genecare Research Institute Co Ltd | 4-aminopyrimidine derivative and medicinal composition containing the compound |
EP2225226B1 (en) * | 2007-12-26 | 2016-08-17 | Critical Outcome Technologies, Inc. | Compounds and their use in a method for treatment of cancer |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
HUE035029T2 (en) | 2008-05-21 | 2018-03-28 | Ariad Pharma Inc | Phosphorous derivatives as kinase inhibitors |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
TWI546290B (en) * | 2008-06-27 | 2016-08-21 | 賽基艾維洛米斯研究股份有限公司 | Heteroaryl compounds and uses thereof |
CN102215816A (en) | 2008-09-03 | 2011-10-12 | 沃泰克斯药物股份有限公司 | Co-crystals and pharmaceutical formulations comprising the same |
EP2349235A1 (en) | 2008-11-07 | 2011-08-03 | Triact Therapeutics, Inc. | Use of catecholic butane derivatives in cancer therapy |
ES2468391T3 (en) | 2008-12-22 | 2014-06-16 | Millennium Pharmaceuticals, Inc. | Combination of Aurora kinase inhibitors and anti-CD20 antibodies |
US8278299B2 (en) | 2008-12-30 | 2012-10-02 | Rigel Pharmaceuticals, Inc. | Pyrimidinediamine kinase inhibitors |
CN102292333B (en) * | 2009-01-15 | 2015-05-13 | 里格尔药品股份有限公司 | Protein kinase c inhibitors and uses thereof |
TWI641593B (en) | 2009-01-16 | 2018-11-21 | 美商艾克塞里克斯公司 | Pharmaceutical composition comprising malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide and use thereof |
ES2635504T3 (en) | 2009-01-21 | 2017-10-04 | Rigel Pharmaceuticals, Inc. | N2- (3-pyridyl or phenyl) -N4- (4-piperidyl) -2,4-pyrimidinadiamine derivatives useful in the treatment of inflammatory, toimmune or proliferative diseases |
CN102356075B (en) | 2009-01-23 | 2015-06-10 | 里格尔药品股份有限公司 | Compositions and methods for inhibition of the jak pathway |
US11464781B2 (en) | 2009-02-25 | 2022-10-11 | Intra-Cellular Therapies, Inc. | PDE1 inhibitors for ophthalmic disorders |
US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
JP2012519170A (en) | 2009-02-26 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | INSITU method for monitoring EMT status of tumor cells in vivo |
WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099364A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010107968A1 (en) | 2009-03-18 | 2010-09-23 | Osi Pharmaceuticals, Inc. | Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor |
ES2659725T3 (en) | 2009-05-05 | 2018-03-19 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and disorder treatment procedure |
WO2010132127A1 (en) | 2009-05-13 | 2010-11-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
JO3635B1 (en) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | Solid pharmaceutical compositions and processes for their production |
EP2459195A1 (en) * | 2009-07-28 | 2012-06-06 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
SG10201507362TA (en) | 2009-08-05 | 2015-10-29 | Intra Cellular Therapies Inc | Novel Regulatory Proteins And Inhibitors |
UA108618C2 (en) | 2009-08-07 | 2015-05-25 | APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT | |
JP2013510564A (en) | 2009-11-13 | 2013-03-28 | パンガエア ビオテック、ソシエダッド、リミターダ | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
WO2011068898A1 (en) | 2009-12-01 | 2011-06-09 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
KR20130005263A (en) | 2009-12-30 | 2013-01-15 | 아르퀼 인코포레이티드 | Substituted naphthalenyl-pyrimidine compounds |
CN104031049A (en) | 2010-02-19 | 2014-09-10 | 米伦纽姆医药公司 | Crystalline Forms Of Aurora Kinase Inhibitor |
CA2999435A1 (en) | 2010-04-01 | 2011-10-06 | Critical Outcome Technologies Inc. | Compounds and method for treatment of hiv |
JP6035238B2 (en) | 2010-07-21 | 2016-11-30 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Protein kinase C inhibitor and use thereof |
KR101937495B1 (en) | 2010-07-28 | 2019-01-10 | 리겔 파마슈티칼스, 인크. | Compositions and methods for inhibition of the jak pathway |
BR112013003388A2 (en) | 2010-08-10 | 2016-07-12 | Celgene Avilomics Res Inc | besylate salt of a btk inhibitor |
ES2635713T3 (en) | 2010-11-01 | 2017-10-04 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
WO2012061299A1 (en) | 2010-11-01 | 2012-05-10 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
EP2637502B1 (en) | 2010-11-10 | 2018-01-10 | Celgene CAR LLC | Mutant-selective egfr inhibitors and uses thereof |
EP2468883A1 (en) | 2010-12-22 | 2012-06-27 | Pangaea Biotech S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
US9134297B2 (en) | 2011-01-11 | 2015-09-15 | Icahn School Of Medicine At Mount Sinai | Method and compositions for treating cancer and related methods |
EP2492688A1 (en) | 2011-02-23 | 2012-08-29 | Pangaea Biotech, S.A. | Molecular biomarkers for predicting response to antitumor treatment in lung cancer |
WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
EP2694486B1 (en) * | 2011-04-01 | 2018-01-10 | University of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
BR112013025387B1 (en) | 2011-04-01 | 2021-07-27 | University Of Utah Research Foundation | REPLACED N-FENYLPYRIMIDIN-2-AMINE ANALOGUE COMPOUNDS AS KINASE AXL INHIBITORS, USE OF SUCH COMPOUNDS FOR THE TREATMENT OF AN UNCONTROLLED CELL PROLIFERATION DISORDER, AS WELL AS KIT INCLUDING SUCH COMPOUNDS |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
CN103501612B (en) | 2011-05-04 | 2017-03-29 | 阿里亚德医药股份有限公司 | The compound that cell is bred in cancer caused by suppression EGF-R ELISA |
PL3409278T3 (en) | 2011-07-21 | 2021-02-22 | Sumitomo Pharma Oncology, Inc. | Heterocyclic protein kinase inhibitors |
SG10201910984XA (en) | 2011-07-27 | 2020-01-30 | Astrazeneca Ab | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
CA2845179A1 (en) | 2011-08-31 | 2013-03-07 | Genentech, Inc. | Diagnostic markers |
JP2014531213A (en) | 2011-09-30 | 2014-11-27 | ジェネンテック, インコーポレイテッド | Diagnostic methylation markers for epithelial or mesenchymal phenotype and response to EGFR kinase inhibitors in tumors or tumor cells |
JP2014532658A (en) | 2011-10-28 | 2014-12-08 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | Methods for treating Breton tyrosine kinase diseases or disorders |
BR112014022789B1 (en) | 2012-03-15 | 2022-04-19 | Celgene Car Llc | Solid forms of an epidermal growth factor receptor kinase inhibitor, pharmaceutical composition and uses thereof |
CA2866857C (en) | 2012-03-15 | 2021-03-09 | Celgene Avilomics Research, Inc. | Salts of an epidermal growth factor receptor kinase inhibitor |
US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
WO2013152198A1 (en) * | 2012-04-04 | 2013-10-10 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
WO2013190089A1 (en) | 2012-06-21 | 2013-12-27 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting outcome in lung cancer |
US8809359B2 (en) | 2012-06-29 | 2014-08-19 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine bicyclic compounds and uses thereof |
AU2013299922B2 (en) | 2012-08-07 | 2018-06-21 | Janssen Pharmaceutica Nv | Process for the preparation of heterocyclic ester derivatives |
JOP20180012A1 (en) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | Sulfonylation process using nonafluorobutanesulfonyl fluoride |
EP3680238A1 (en) | 2012-10-04 | 2020-07-15 | University of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
JP6313772B2 (en) | 2012-10-04 | 2018-04-18 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | Substituted N- (3- (pyrimidin-4-yl) phenyl) acrylamide analogs that are tyrosine receptor kinase BTK inhibitors |
WO2014089112A1 (en) | 2012-12-04 | 2014-06-12 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
WO2014100748A1 (en) | 2012-12-21 | 2014-06-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US9145387B2 (en) | 2013-02-08 | 2015-09-29 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
JP6549040B2 (en) | 2013-02-17 | 2019-07-24 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | New use |
GB201303109D0 (en) * | 2013-02-21 | 2013-04-10 | Domainex Ltd | Novel pyrimidine compounds |
EP2961412A4 (en) | 2013-02-26 | 2016-11-09 | Triact Therapeutics Inc | Cancer therapy |
WO2014151900A1 (en) | 2013-03-14 | 2014-09-25 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
EP2970205B1 (en) * | 2013-03-14 | 2019-05-08 | Tolero Pharmaceuticals, Inc. | Jak2 and alk2 inhibitors and methods for their use |
WO2014151409A1 (en) | 2013-03-15 | 2014-09-25 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2014152716A1 (en) * | 2013-03-15 | 2014-09-25 | President And Fellows Of Harvard College | Substituted heterocyclic compounds for treating or preventing viral infections |
ES2717688T3 (en) | 2013-03-15 | 2019-06-24 | Intra Cellular Therapies Inc | PDE1 inhibitors for use in the treatment and / or prevention of CNS lesions, and diseases, disorders or injuries of SNP |
WO2014147246A1 (en) | 2013-03-21 | 2014-09-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression |
JP6360881B2 (en) | 2013-03-22 | 2018-07-18 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | Combination of catalytic MTORC1 / 2 inhibitor and selective inhibitor of Aurora A kinase |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
AR096654A1 (en) | 2013-06-20 | 2016-01-27 | Ab Science | DERIVATIVES OF BENZIMIDAZOL AS SELECTIVE INHIBITORS OF PROTEIN QUINASA |
CN103408501B (en) * | 2013-08-14 | 2016-03-09 | 合肥医工医药有限公司 | Benzylpyrimidine derivative, its preparation method and medicinal use thereof |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
WO2015035410A1 (en) | 2013-09-09 | 2015-03-12 | Triact Therapeutic, Inc. | Cancer therapy |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
PL3126352T3 (en) | 2014-04-04 | 2019-04-30 | Syros Pharmaceuticals Inc | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2015156674A2 (en) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
TWI681954B (en) | 2014-06-12 | 2020-01-11 | 美商西爾拉癌症醫學公司 | N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide |
ES2732442T3 (en) | 2014-06-20 | 2019-11-22 | Intra Cellular Therapies Inc | Organic compounds |
TWI686394B (en) | 2014-08-07 | 2020-03-01 | 美商內胞醫療公司 | Organic compounds |
US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
WO2016025561A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Forms and compositions of an erk inhibitor |
KR102332957B1 (en) | 2014-09-17 | 2021-11-29 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | Compounds and methods |
AU2015371312B2 (en) | 2014-12-24 | 2022-01-27 | Genentech, Inc. | Therapeutic, diagnostic and prognostic methods for cancer of the bladder |
CN106188029B (en) * | 2015-05-05 | 2018-09-18 | 山东轩竹医药科技有限公司 | Two and ring class anaplastic lymphoma kinase inhibitor |
US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
MA44666A (en) * | 2016-04-15 | 2019-02-20 | Epizyme Inc | AMINE SUBSTITUTED ARYL OR HETERARYL COMPOUNDS USED AS EHMT1 AND EHMT2 INHIBITORS |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
EP3509589B1 (en) | 2016-09-12 | 2021-11-17 | Intra-Cellular Therapies, Inc. | Novel uses |
ES2894255T3 (en) | 2016-12-22 | 2022-02-14 | Amgen Inc | Benzoisothiazole derivatives, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as KRAS G12C inhibitors to treat lung cancer pancreatic or colorectal |
AU2018254577A1 (en) | 2017-04-21 | 2019-12-05 | Epizyme, Inc. | Combination therapies with EHMT2 inhibitors |
JOP20190272A1 (en) | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
UY37870A (en) | 2017-09-08 | 2019-03-29 | Amgen Inc | KRAS G12C INHIBITORS AND METHODS TO USE THEM FIELD OF THE INVENTION |
JP7401442B2 (en) | 2018-01-31 | 2023-12-19 | イントラ-セルラー・セラピーズ・インコーポレイテッド | new use |
JP2021524835A (en) | 2018-04-05 | 2021-09-16 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | AXL Kinase Inhibitors and Their Use |
MX2020010556A (en) | 2018-04-13 | 2021-03-02 | Sumitomo Pharma Oncology Inc | Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer. |
CA3099118A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
US11090304B2 (en) | 2018-05-04 | 2021-08-17 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
AU2019265822A1 (en) | 2018-05-10 | 2020-11-19 | Amgen Inc. | KRAS G12C inhibitors for the treatment of cancer |
MA52765A (en) | 2018-06-01 | 2021-04-14 | Amgen Inc | KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE |
MA52780A (en) | 2018-06-11 | 2021-04-14 | Amgen Inc | KRAS G12C INHIBITORS FOR CANCER TREATMENT |
AU2019336588B2 (en) | 2018-06-12 | 2022-07-28 | Amgen Inc. | KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer |
MX2021000977A (en) | 2018-07-26 | 2021-04-12 | Sumitomo Pharma Oncology Inc | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same. |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
CA3115038A1 (en) | 2018-10-04 | 2020-04-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Egfr inhibitors for treating keratodermas |
JP2020090482A (en) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Improved synthesis of key intermediate of kras g12c inhibitor compound |
MX2021005700A (en) | 2018-11-19 | 2021-07-07 | Amgen Inc | Kras g12c inhibitors and methods of using the same. |
JP7377679B2 (en) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer |
MX2021007156A (en) | 2018-12-20 | 2021-08-16 | Amgen Inc | Kif18a inhibitors. |
WO2020132653A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
MX2021007158A (en) | 2018-12-20 | 2021-08-16 | Amgen Inc | Heteroaryl amides useful as kif18a inhibitors. |
EP3897855B1 (en) | 2018-12-20 | 2023-06-07 | Amgen Inc. | Kif18a inhibitors |
JP2022520361A (en) | 2019-02-12 | 2022-03-30 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | Pharmaceuticals containing heterocyclic protein kinase inhibitors |
AU2020232616A1 (en) | 2019-03-01 | 2021-09-09 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
SG11202109036WA (en) | 2019-03-01 | 2021-09-29 | Revolution Medicines Inc | Bicyclic heteroaryl compounds and uses thereof |
US20220296595A1 (en) * | 2019-05-05 | 2022-09-22 | Qilu Regor Therapeutics Inc. | Cdk inhibitors |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
CN114144414A (en) | 2019-05-21 | 2022-03-04 | 美国安进公司 | Solid state form |
AR119009A1 (en) * | 2019-05-29 | 2021-11-17 | Syngenta Crop Protection Ag | MICROBICIDE ALCOPYPYRIDINE AND ALCOXYPYRIMIDINE DERIVATIVES |
AU2020324963A1 (en) | 2019-08-02 | 2022-02-24 | Amgen Inc. | KIF18A inhibitors |
MX2022001295A (en) | 2019-08-02 | 2022-02-22 | Amgen Inc | Kif18a inhibitors. |
EP4007638A1 (en) | 2019-08-02 | 2022-06-08 | Amgen Inc. | Pyridine derivatives as kif18a inhibitors |
MX2022001296A (en) | 2019-08-02 | 2022-02-22 | Amgen Inc | Kif18a inhibitors. |
JP2022543843A (en) | 2019-08-08 | 2022-10-14 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Compounds and methods for treating cytokine release syndrome |
WO2021081212A1 (en) | 2019-10-24 | 2021-04-29 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
TW202132314A (en) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras inhibitors |
CR20220240A (en) | 2019-11-04 | 2022-08-03 | Revolution Medicines Inc | Ras inhibitors |
JP2022553858A (en) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | RAS inhibitor |
CA3156359A1 (en) | 2019-11-08 | 2021-05-14 | Adrian Liam Gill | Bicyclic heteroaryl compounds and uses thereof |
US20230192681A1 (en) | 2019-11-14 | 2023-06-22 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
WO2021097207A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
EP4065231A1 (en) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
TW202140011A (en) | 2020-01-07 | 2021-11-01 | 美商銳新醫藥公司 | Shp2 inhibitor dosing and methods of treating cancer |
KR20230042600A (en) | 2020-06-18 | 2023-03-28 | 레볼루션 메디슨즈, 인크. | Methods of Delaying, Preventing, and Treating Acquired Resistance to RAS Inhibitors |
AU2021344830A1 (en) | 2020-09-03 | 2023-04-06 | Revolution Medicines, Inc. | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as ras inhibitors in the treatment of cancer |
JP2024501280A (en) | 2020-12-22 | 2024-01-11 | キル・レガー・セラピューティクス・インコーポレーテッド | SOS1 inhibitors and their uses |
AR125787A1 (en) | 2021-05-05 | 2023-08-16 | Revolution Medicines Inc | RAS INHIBITORS |
CN117500811A (en) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | Covalent RAS inhibitors and uses thereof |
CR20230570A (en) | 2021-05-05 | 2024-01-22 | Revolution Medicines Inc | Ras inhibitors |
AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
TW202340214A (en) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023150197A1 (en) * | 2022-02-03 | 2023-08-10 | Nexys Therapeutics, Inc. | Aryl hydrocarbon receptor agonists and uses thereof |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1285932A (en) | 1960-12-26 | 1962-03-02 | Nord Aviation | Hollow charge |
US3947467A (en) | 1973-08-02 | 1976-03-30 | Eli Lilly And Company | 3-(5-Nitro-2-imidazolyl) pyrazoles |
FR2257272B1 (en) * | 1974-01-15 | 1978-08-25 | Pharmascience Labo | |
US4193926A (en) * | 1974-03-20 | 1980-03-18 | Schering Aktiengesellschaft | 4-(Polyalkoxy phenyl)-2-pyrrolidones |
DE2413935A1 (en) * | 1974-03-20 | 1975-10-16 | Schering Ag | 4- (POLYALCOXY-PHENYL) -2-PYRROLIDONE |
DE2541855A1 (en) * | 1975-09-18 | 1977-03-31 | Schering Ag | 4- (POLYALCOXY-PHENYL) -2-PYRROLIDONE II |
FR2313422A2 (en) | 1975-06-02 | 1976-12-31 | Labaz | Stabilisers for vinyl chloride polymers - comprising substd. (2)-phenyl-indoles |
SU888821A3 (en) * | 1976-12-03 | 1981-12-07 | Шеринг Аг (Инофирма) | Method of preparing 5-(substituted phehyl)-oxazolidinones or their sulphur-containing analogs |
EP0006298B1 (en) * | 1978-06-15 | 1982-03-31 | Imperial Chemical Industries Plc | Anti-inflammatory 1-phenyl-2-aminoethanol derivatives, pharmaceutical compositions thereof for topical use, and processes for their manufacture |
DE3374313D1 (en) | 1982-12-23 | 1987-12-10 | Smith Kline French Lab | AMINOPYRIMIDINONE DERIVATIVES AS HISTAMINE H1-ANTAGONISTS |
IT1161221B (en) * | 1983-04-21 | 1987-03-18 | Ripharm Srl | COMPOUND FOR PSORIASIS TREATMENT |
US4694009A (en) | 1984-06-25 | 1987-09-15 | Ciba-Geigy Corporation | Pesticidal compositions |
US4788195A (en) * | 1986-01-13 | 1988-11-29 | American Cyanamid Company | 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines |
US4876252A (en) * | 1986-01-13 | 1989-10-24 | American Cyanamid Company | 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines |
EP0233461B2 (en) * | 1986-01-13 | 2002-05-29 | American Cyanamid Company | 4,5,6-Substituted-2-pyrimidinamines |
US5128358A (en) * | 1988-01-19 | 1992-07-07 | Pfizer Inc. | Aryl substituted nitrogen heterocyclic antidepressants |
HU215433B (en) * | 1986-04-29 | 2000-05-28 | Pfizer Inc. | Process for producing new 2-oxo-5-phenyl-pyrimidin derivatives |
US4921862A (en) * | 1986-05-29 | 1990-05-01 | Syntex (U.S.A.) Inc. | Carbostyril derivatives as combined thromboxane synthetase and cyclic-amp phosphodiesterase inhibitors |
US4792561A (en) * | 1986-05-29 | 1988-12-20 | Syntex (U.S.A.) Inc. | Carbostyril derivatives as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors |
CN1030415A (en) | 1987-02-20 | 1989-01-18 | 山之内制药株式会社 | Saturated heterocycle carboxamide derivatives and its preparation method |
US4971959A (en) * | 1987-04-14 | 1990-11-20 | Warner-Lambert Company | Trisubstituted phenyl analogs having activity for congestive heart failure |
US5274002A (en) * | 1987-04-14 | 1993-12-28 | Warner-Lambert Company | Trisubstituted phenyl analogs having activity for congestive heart failure |
DE3882821D1 (en) * | 1987-06-11 | 1993-09-09 | Ciba Geigy Ag | MICROBICIDES. |
US4966622A (en) * | 1988-04-12 | 1990-10-30 | Ciba-Geigy Corporation | N-phenyl-N-pyrimidin-2-ylureas |
US4897396A (en) * | 1988-06-03 | 1990-01-30 | Ciba-Geigy Corporation | 2-phenylamino pyrimidine derivatives and their uses as microbicides |
DK0469013T3 (en) * | 1989-04-17 | 1995-10-02 | Byk Gulden Lomberg Chem Fab | New aryl pyridazines, their preparation, their use, and drugs containing them |
US5164372A (en) | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
JPH075572B2 (en) * | 1989-08-18 | 1995-01-25 | 積水化学工業株式会社 | 2- [2- (2-hydroxyphenyl) vinylpyrazine and method for producing the same |
JPH0377923A (en) * | 1989-08-18 | 1991-04-03 | Sekisui Chem Co Ltd | Organic nonlinear optical material |
DE4003919A1 (en) * | 1990-02-09 | 1991-08-14 | Basf Ag | HETEROARYLALKENES, METHODS AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION AND THEIR USE |
GB9007762D0 (en) * | 1990-04-05 | 1990-06-06 | Beecham Group Plc | Novel compounds |
WO1991016892A1 (en) * | 1990-04-27 | 1991-11-14 | Rorer International (Holdings), Inc. | Styryl compounds which inhibit egf receptor protein tyrosine kinase |
AU8229291A (en) * | 1990-07-10 | 1992-02-04 | Smithkline Beecham Corporation | Oxamides |
US5124455A (en) * | 1990-08-08 | 1992-06-23 | American Home Products Corporation | Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents |
WO1992006085A1 (en) * | 1990-09-28 | 1992-04-16 | Smith Kline & French Laboratories Limited | Phenylpyridinol derivatives as medicaments |
DE59109027D1 (en) * | 1990-10-16 | 1998-08-13 | Byk Gulden Lomberg Chem Fab | Arylpyridazinone |
EP0557408A4 (en) * | 1990-11-06 | 1993-10-27 | Smith-Kline Beecham Corporation | Imidazolidinone compounds |
GB9027055D0 (en) * | 1990-12-13 | 1991-02-06 | Sandoz Ltd | Organic compounds |
IE71647B1 (en) * | 1991-01-28 | 1997-02-26 | Rhone Poulenc Rorer Ltd | Benzamide derivatives |
US5698711A (en) | 1991-01-28 | 1997-12-16 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
US5449676A (en) * | 1991-04-26 | 1995-09-12 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pyridazines |
US5191084A (en) * | 1991-05-01 | 1993-03-02 | American Home Products Corporation | Phenyl pyrazolidinones as bronchodilators and anti-inflammatory agents |
PT100441A (en) * | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | PIRROLIDINONES, ITS PREPARATION PROCESS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE |
EP0540165A1 (en) * | 1991-10-03 | 1993-05-05 | Zeneca Limited | Alkanoic acid derivatives |
CA2080554A1 (en) * | 1991-10-15 | 1993-04-16 | Mitsubishi Chemical Corporation | Styrene derivatives |
DE4136921A1 (en) * | 1991-11-11 | 1993-05-13 | Knoll Ag | METHOD FOR SEPARATING 5-METHYL-TETRAHYDROFOLIC ACID |
US5326898A (en) * | 1992-02-11 | 1994-07-05 | Allergan, Inc. | Substituted phenylethenyl compounds having retinoid-like biological activity |
EP0633775B1 (en) * | 1992-04-02 | 2000-05-31 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and for inhibiting production of tumor necrosis factor |
TW225528B (en) * | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
GB9212693D0 (en) * | 1992-06-15 | 1992-07-29 | Celltech Ltd | Chemical compounds |
GB9212673D0 (en) * | 1992-06-15 | 1992-07-29 | Celltech Ltd | Chemical compounds |
IL106517A0 (en) * | 1992-07-28 | 1994-08-26 | Rhone Poulenc Rorer Ltd | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic or heteroatom containing linking group |
GB9222253D0 (en) * | 1992-10-23 | 1992-12-09 | Celltech Ltd | Chemical compounds |
DK0672031T3 (en) * | 1992-12-02 | 2003-06-10 | Pfizer | Catechol dieters as selective PDE IV inhibitors |
DK0674631T3 (en) * | 1992-12-17 | 2000-04-10 | Pfizer | Substituted pyrazoles as CRF antogonists |
TW263495B (en) * | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
US5622977A (en) * | 1992-12-23 | 1997-04-22 | Celltech Therapeutics Limited | Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same |
GB9226830D0 (en) * | 1992-12-23 | 1993-02-17 | Celltech Ltd | Chemical compounds |
GB9304919D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
GB9304920D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
GB9315595D0 (en) * | 1993-07-28 | 1993-09-08 | Res Inst Medicine Chem | New compounds |
WO1995009847A1 (en) * | 1993-10-01 | 1995-04-13 | Ciba-Geigy Ag | Pyrimidineamine derivatives and processes for the preparation thereof |
US5543520A (en) * | 1993-10-01 | 1996-08-06 | Ciba-Geigy Corporation | Pyrimidine derivatives |
EP0672042B1 (en) * | 1993-10-01 | 2006-05-03 | Novartis AG | Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof |
US5728708A (en) * | 1993-10-01 | 1998-03-17 | Novartis Corporation | Pharmacologically active pyridine derivatives and processes for the preparation thereof |
CZ283564B6 (en) | 1993-11-26 | 1998-05-13 | Pfizer Inc. | 3-aryl-2-isoxazoline-5-hydroxamic acids and pharmaceutical compositions based thereon |
GB9326173D0 (en) * | 1993-12-22 | 1994-02-23 | Celltech Ltd | Chemical compounds and process |
ATE260911T1 (en) | 1993-12-22 | 2004-03-15 | Celltech R&D Ltd | TRISUBSUTITUTED PHENYL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS PHOSPHODIESTERASE (TYPE IV) INHIBITORS |
GB9326699D0 (en) | 1993-12-22 | 1994-03-02 | Celltech Ltd | Chemical compounds |
US5691376A (en) | 1994-02-17 | 1997-11-25 | American Home Products Corporation | Substituted biphenyl derivatives |
US5559137A (en) * | 1994-05-16 | 1996-09-24 | Smithkline Beecham Corp. | Compounds |
AU2265495A (en) * | 1994-06-06 | 1996-01-04 | Pfizer Inc. | Substituted pyrazoles having corticotropin-releasing factor (crf) antagonist activity |
US5786354A (en) | 1994-06-21 | 1998-07-28 | Celltech Therapeutics, Limited | Tri-substituted phenyl derivatives and processes for their preparation |
US6245774B1 (en) * | 1994-06-21 | 2001-06-12 | Celltech Therapeutics Limited | Tri-substituted phenyl or pyridine derivatives |
GB9412573D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
GB9412571D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
GB9412672D0 (en) * | 1994-06-23 | 1994-08-10 | Celltech Ltd | Chemical compounds |
WO1996014843A2 (en) * | 1994-11-10 | 1996-05-23 | Cor Therapeutics, Inc. | Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases |
CA2182946A1 (en) | 1994-12-23 | 1996-07-04 | Raymond John Owens | Human phosphodiesterase type ivc, and its production and use |
US5593997A (en) * | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
US5776699A (en) * | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
CZ98998A3 (en) * | 1995-10-02 | 1998-10-14 | F. Hoffmann-La Roche Ag | Pyrimidine derivatives as antagonists of 5ht2c receptor |
GB9526245D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
GB9526243D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
GB9526246D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
GB9608435D0 (en) | 1996-04-24 | 1996-06-26 | Celltech Therapeutics Ltd | Chemical compounds |
GB9625184D0 (en) | 1996-12-04 | 1997-01-22 | Celltech Therapeutics Ltd | Chemical compounds |
-
1995
- 1995-11-20 GB GBGB9523675.8A patent/GB9523675D0/en active Pending
-
1996
- 1996-11-19 US US08/753,041 patent/US5958935A/en not_active Expired - Fee Related
- 1996-11-20 AU AU76314/96A patent/AU7631496A/en not_active Abandoned
- 1996-11-20 WO PCT/GB1996/002854 patent/WO1997019065A1/en active IP Right Grant
- 1996-11-20 ES ES96939171T patent/ES2195020T3/en not_active Expired - Lifetime
- 1996-11-20 DE DE69627179T patent/DE69627179T2/en not_active Expired - Fee Related
- 1996-11-20 EP EP96939171A patent/EP0862560B1/en not_active Expired - Lifetime
-
1999
- 1999-02-16 US US09/249,760 patent/US6235746B1/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
See references of WO9719065A1 * |
Also Published As
Publication number | Publication date |
---|---|
US6235746B1 (en) | 2001-05-22 |
EP0862560B1 (en) | 2003-04-02 |
US5958935A (en) | 1999-09-28 |
DE69627179D1 (en) | 2003-05-08 |
GB9523675D0 (en) | 1996-01-24 |
DE69627179T2 (en) | 2004-01-29 |
WO1997019065A1 (en) | 1997-05-29 |
ES2195020T3 (en) | 2003-12-01 |
AU7631496A (en) | 1997-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0862560B1 (en) | Substituted 2-anilinopyrimidines useful as protein kinase inhibitors | |
US6048866A (en) | Substituted 2-anilinopryimidines useful as protein kinase inhibitors | |
EP1187816B1 (en) | 5-cyano-2-aminopyrimidine derivatives | |
US6093716A (en) | Substituted 2-pyrimidineamines and processes for their preparation | |
EP0934304B1 (en) | 2-pyrimidineamine derivatives and processes for their preparation | |
US5922741A (en) | 5-aminopyrazoles useful as tyrosine kinase inhibitors | |
US6600037B1 (en) | 4,5-disubstituted-2-aminopyrimidines | |
WO1998028281A1 (en) | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors | |
EP1133488A1 (en) | Propanoic acid derivatives as integrin inhibitors | |
EP0989985B1 (en) | Fused polycyclic 2-aminopyrimidine derivatives as protein kinase inhibitors | |
US7012076B2 (en) | Bicyclic amine derivatives as inhibitors of class 1 receptor tyrosine kinases | |
WO2002087587A2 (en) | 4-aminosulfonylquinazolines and -quinolines as tyrosine kinase inhibitors | |
JP2006519234A (en) | New compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19980522 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): CH DE ES FR GB IT LI |
|
17Q | First examination report despatched |
Effective date: 20000913 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): CH DE ES FR GB IT LI |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 69627179 Country of ref document: DE Date of ref document: 20030508 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: BOVARD AG PATENTANWAELTE |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20031128 Year of fee payment: 8 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20040105 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041130 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041130 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20041214 Year of fee payment: 9 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20051108 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20051116 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20051117 Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20051120 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20051121 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20051121 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070601 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20061120 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20070731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061120 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061130 |